metformin has been researched along with Overweight in 198 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 9.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 9.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 9.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| "If metformin is proved to slow knee cartilage volume loss and to relieve knee symptoms among overweight knee OA patients, it will have the potential to become a disease modifying drug for knee OA." | 9.51 | Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? Study protocol for a randomized, double-blind, and placebo-controlled trial. ( Cai, X; Dai, L; Ding, C; Guan, S; Guo, D; Lan, X; Lou, A; Luo, J; Mei, Y; Mo, Y; Qu, Y; Ruan, G; Wu, W; Yu, Q; Yuan, S; Zhang, H; Zhang, Y, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 9.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 9.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 9.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 9.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 9.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| "In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 9.34 | Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020) |
| "This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic parameters in overweight women with a recent history of gestational diabetes mellitus." | 9.34 | A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. ( Elkind-Hirsch, KE; Harris, R; Seidemann, E, 2020) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| "Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850-1700 mg of metformin (n = 48) or placebo (n = 49)." | 9.30 | Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. ( Fuchs, FD; Fuchs, SC; Gus, M; Júnior, VC; Moreira, LB; Schaan, BD, 2019) |
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 9.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 9.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 9.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 9.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 9.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications." | 9.27 | Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. ( Aman, MG; Anagnostou, EA; Arnold, LE; Chan, J; Handen, BL; Hastie Adams, R; Hollway, JA; Macklin, E; Marler, S; Newsom, C; Peleg, N; Sanders, KB; Veenstra-VanderWeele, J; Wong, T, 2018) |
| "A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics." | 9.24 | A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Chan, J; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Williams, C; Wong, T, 2017) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 9.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "Both green tea and metformin are used as adjuvants to treat and prevent complications associated with obesity; however, studies comparing their action and interaction in non-diabetic overweight women have not been reported." | 9.24 | Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial. ( Alves Ferreira, M; Borges Botelho, P; Ferreira Stringhini, ML; Guimarães de Moraes, AP; Mota, JF; Oliveira Gomes, AP; Siqueira Guedes Coelho, A, 2017) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 9.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 9.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 9.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 9.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 9.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 9.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 9.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 9.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 9.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 9.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 9.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 9.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| " This study aimed to determine the effect of metformin on body weight, body composition, metabolic risk factors and reproductive hormone levels in overweight or obese young women compared to placebo and comprehensive lifestyle intervention." | 9.15 | The effect of comprehensive lifestyle intervention or metformin on obesity in young women. ( Clifton, PM; Lim, SS; Noakes, M; Norman, RJ, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 9.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "In overweight patients with PCOS with hyperinsulinism, allopregnanolone secretion is impaired and metformin administration restored normal allopregnanolone concentrations modulating both steroid syntheses from the ovaries and from adrenal gland." | 9.14 | Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. ( Casarosa, E; Chierchia, E; Genazzani, AD; Genazzani, AR; Luisi, M; Rattighieri, E; Santagni, S, 2010) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 9.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 9.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS." | 9.13 | Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. ( Bhushan, M; Bhushan, R; Elkind-Hirsch, K; Marrioneaux, O; Vernor, D, 2008) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 9.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "In a randomized, double-blind, cross-over study, we investigated the effect of metformin on blood glucose control and daily insulin dose in overweight patients with Type 1 diabetes." | 9.12 | The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. ( Ahmed, AB; Khan, AS; McLoughney, CR, 2006) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 9.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults." | 9.01 | Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. ( Hui, F; Li, X; Ren, T; Zhang, Y; Zhao, M; Zhao, Q, 2019) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 9.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| "For overweight polycystic ovary syndrome patients, our evidence revealed that EE/CA and EE/SRSP combined with metformin or lifestyle changes can reduce the adverse effects on glucose and lipid metabolism of the use of oral contraceptive agents alone." | 9.01 | The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. ( Li, Q; Liu, M; Mo, T; Shen, C; Wang, A, 2019) |
| "To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases." | 8.98 | The effects of metformin on simple obesity: a meta-analysis. ( Deng, B; Gao, PX; Le, J; Ning, HH; Qin, SL; Wang, Q; Young, CA; Zhang, HQ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 8.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 8.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 8.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| "To assess the efficacy and safety of using metformin in overweight and obese adolescents without related morbidity." | 8.88 | Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. ( Amate, J; Bouza, C; Gutierrez-Torres, LF; López-Cuadrado, T, 2012) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 8.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 8.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "The anti-diabetic drug metformin might reduce prevalence of chronic low back pain in people who are older, overweight, or less active." | 8.31 | The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. ( Carvalho-E-Silva, AP; Ferreira, ML; Ferreira, PH; Harmer, AR; Hartvigsen, J, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 8.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 8.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 8.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 8.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 7.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 7.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 7.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 7.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 7.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 7.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| "To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients." | 7.81 | IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. ( Gong, WJ; Han, XY; Ji, LN; Li, X; Lin, X; Liu, RR; Liu, ZQ; Tang, Q; Xiao, D; Xu, XJ; Yin, JY; Zhang, SM; Zhang, W; Zheng, Y; Zhou, HH, 2015) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 7.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| "We examined the effects of therapy with metformin alone (n = 14) vs metformin with EP (n = 13) on HbA1C and lipid parameters over 10-14 months in 27 overweight girls, drawn from a clinic population of adolescents with PCOS." | 7.79 | Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. ( Bredella, MA; McManus, S; Misra, M, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 7.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 7.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS)." | 7.77 | Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. ( Fatemi, S; Morteza Taghavi, S; Rokni, H, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 7.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 7.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "7%) stopped metformin therapy due to excessive anorexia." | 7.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 7.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 7.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| " Obesity is the most important risk factor to develop this disease and metformin is considered as a first line drug in overweighted diabetic patients." | 7.73 | [Metformin in the treatment of type 2 diabetes in overweighted or obese patients]. ( Costa Zamora, P; Díaz, JM; González Alvaro, A; Martín Muñoz, MC; Muros Bayo, JM, 2005) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 7.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 7.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| "Metformin treatment had a small but positive effect on bone quality in the peripheral skeleton, reduced weight gain, and resulted in a more beneficial body composition compared with placebo in insulin-treated patients with type 2 diabetes." | 7.01 | Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. ( Almdal, TP; Boesgaard, TW; Breum, L; Eiken, P; Gade-Rasmussen, B; Gluud, C; Hemmingsen, B; Lund, SS; Lundby-Christensen, L; Madsbad, S; Mathiesen, ER; Nordklint, AK; Perrild, H; Sneppen, SB; Tarnow, L; Thorsteinsson, B; Vestergaard, H; Vestergaard, P, 2021) |
| " Primary endpoint was HbA1c, while secondary endpoints were body weight, frequency of hypoglycaemia, blood pressure, lipids, insulin dosage and self-monitored blood glucose profiles were measured." | 6.74 | The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. ( Beck-Nielsen, H; Henriksen, JE; Jacobsen, IB, 2009) |
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 5.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity." | 5.69 | Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. ( Bianzano, S; Heise, T; Nordaby, M; Peil, B; Plum-Mörschel, L, 2023) |
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 5.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 5.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| "Twelve weeks of treatment with metformin resulted in a significant reduction in body weight and improved insulin sensitivity, but IHTG content and FA oxidation remained unchanged." | 5.51 | Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. ( Charlton, C; Cornfield, T; Green, CJ; Hazlehurst, JM; Hodson, L; Marjot, T; McCullagh, J; Moolla, A; Pinnick, KE; Tomlinson, JW; Walsby-Tickle, J; Westcott, F, 2022) |
| "If metformin is proved to slow knee cartilage volume loss and to relieve knee symptoms among overweight knee OA patients, it will have the potential to become a disease modifying drug for knee OA." | 5.51 | Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? Study protocol for a randomized, double-blind, and placebo-controlled trial. ( Cai, X; Dai, L; Ding, C; Guan, S; Guo, D; Lan, X; Lou, A; Luo, J; Mei, Y; Mo, Y; Qu, Y; Ruan, G; Wu, W; Yu, Q; Yuan, S; Zhang, H; Zhang, Y, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 5.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 5.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 5.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 5.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Metformin treatment increases serum cartonectin levels in these women and in omental AT explants." | 5.39 | Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. ( Adya, R; Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2013) |
| "Metformin has been proposed as a potential drug treatment to reduce liver steatosis." | 5.35 | Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. ( Tessari, P; Tiengo, A, 2008) |
| "To determine the separated and combined effects of metformin and exercise on insulin sensitivity and free-living glycemic control in overweight individuals with prediabetes/type 2 diabetes (T2DM)." | 5.34 | Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. ( Mora-Rodríguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 5.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| "In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 5.34 | Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020) |
| "This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic parameters in overweight women with a recent history of gestational diabetes mellitus." | 5.34 | A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. ( Elkind-Hirsch, KE; Harris, R; Seidemann, E, 2020) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 5.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| "Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850-1700 mg of metformin (n = 48) or placebo (n = 49)." | 5.30 | Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. ( Fuchs, FD; Fuchs, SC; Gus, M; Júnior, VC; Moreira, LB; Schaan, BD, 2019) |
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 5.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 5.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 5.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 5.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 5.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications." | 5.27 | Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. ( Aman, MG; Anagnostou, EA; Arnold, LE; Chan, J; Handen, BL; Hastie Adams, R; Hollway, JA; Macklin, E; Marler, S; Newsom, C; Peleg, N; Sanders, KB; Veenstra-VanderWeele, J; Wong, T, 2018) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 5.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "Both green tea and metformin are used as adjuvants to treat and prevent complications associated with obesity; however, studies comparing their action and interaction in non-diabetic overweight women have not been reported." | 5.24 | Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial. ( Alves Ferreira, M; Borges Botelho, P; Ferreira Stringhini, ML; Guimarães de Moraes, AP; Mota, JF; Oliveira Gomes, AP; Siqueira Guedes Coelho, A, 2017) |
| " We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)." | 5.24 | Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. ( Anholm, C; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Larsen, BS; Madsbad, S; Nielsen, OW; Olsen, RH; Sajadieh, A, 2017) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 5.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 5.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 5.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 5.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "The effects of a 1year period of intensive lifestyle change aimed at achieving 7% weight loss or metformin 850mg twice daily versus placebo on HDL-C were assessed in 3070 participants with impaired glucose tolerance, and on HDL particle concentration (HDL-P) and size in a subgroup of 1645 individuals." | 5.22 | Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. ( Bray, G; Goldberg, RB; Horton, E; Kitabchi, A; Krakoff, J; Marcovina, S; Mather, K; Mele, L; Orchard, T; Perreault, L; Temprosa, M; White, N, 2016) |
| "To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs)." | 5.22 | Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. ( Aronson, R; Gentile, S; Guerci, B; Hanefeld, M; Heller, S; Perfetti, R; Rosenstock, J; Roy-Duval, C; Souhami, E; Tinahones, FJ; Wardecki, M; Ye, J, 2016) |
| "Secondary analysis of men (n=886) participating in the Diabetes Prevention Program which randomized glucose-intolerant, overweight men to ILS, metformin, or placebo between 1996 and 1999." | 5.22 | Testosterone and depressive symptoms among men in the Diabetes Prevention Program. ( Aroda, VR; Barrett-Connor, E; Bray, GA; Christophi, CA; Golden, SH; Horton, ES; Kim, C; Labrie, F; Mather, KJ; Pi-Sunyer, X, 2016) |
| "This study tests the effectiveness of expert guidelines for diabetes prevention: lifestyle intervention with addition of metformin, when required, among people with prediabetes." | 5.22 | The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial. ( Ali, MK; Anjana, RM; Mohan, V; Narayan, KM; Ranjani, H; Staimez, LR; Weber, MB, 2016) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 5.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| " Women were randomized to intensive lifestyle change (ILS) with the goals of weight reduction of at least 7% of initial weight and 150 min per week of moderate-intensity exercise, metformin 850 mg twice a day, or placebo administered twice a day." | 5.20 | Weight loss increases follicle stimulating hormone in overweight postmenopausal women [corrected]. ( Barrett-Connor, E; Golden, SH; Kim, C; Kong, S; Labrie, F; Nan, B; Randolph, JF, 2015) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 5.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 5.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| "The Diabetes Prevention Program randomized overweight or obese dysglycemic participants to lifestyle change with the goals of weight reduction of >7% of initial weight and 150 minutes per week of exercise, metformin, or placebo." | 5.19 | Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. ( Barrett-Connor, E; Golden, SH; Kim, C; Kong, S; Mather, KJ; Nan, B; Randolph, JF, 2014) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 5.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 5.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 5.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 5.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 5.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| " This study aimed to determine the effect of metformin on body weight, body composition, metabolic risk factors and reproductive hormone levels in overweight or obese young women compared to placebo and comprehensive lifestyle intervention." | 5.15 | The effect of comprehensive lifestyle intervention or metformin on obesity in young women. ( Clifton, PM; Lim, SS; Noakes, M; Norman, RJ, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 5.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The aim of this study was to assess novel inflammatory markers [adipokines leptin, adiponectin, and leptinadiponectin ratio (L/A)] in overweight women with and without PCOS and to examine alterations in these markers [aldosterone, leptin, adiponectin, and L/A] with pharmacological interventions modulating insulin resistance (IR) in PCOS." | 5.14 | Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention. ( Hutchison, SK; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| " The modest weight loss with metformin was maintained." | 5.14 | 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. ( Brenneman, AT; Brown-Friday, JO; Christophi, CA; Fowler, SE; Goldberg, R; Hamman, RF; Hoffman, HJ; Knowler, WC; Nathan, DM; Venditti, E, 2009) |
| "In overweight patients with PCOS with hyperinsulinism, allopregnanolone secretion is impaired and metformin administration restored normal allopregnanolone concentrations modulating both steroid syntheses from the ovaries and from adrenal gland." | 5.14 | Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. ( Casarosa, E; Chierchia, E; Genazzani, AD; Genazzani, AR; Luisi, M; Rattighieri, E; Santagni, S, 2010) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 5.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 5.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS." | 5.13 | Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. ( Bhushan, M; Bhushan, R; Elkind-Hirsch, K; Marrioneaux, O; Vernor, D, 2008) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 5.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "In a randomized, double-blind, cross-over study, we investigated the effect of metformin on blood glucose control and daily insulin dose in overweight patients with Type 1 diabetes." | 5.12 | The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. ( Ahmed, AB; Khan, AS; McLoughney, CR, 2006) |
| "In overweight women with PCOS, metformin and low- and high-dose OCP preparations have similar efficacy but differential effects on insulin resistance and arterial function." | 5.12 | Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. ( McGrath, BP; Meyer, C; Teede, HJ, 2007) |
| "For overweight women with PCOS, both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia." | 5.05 | Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS. ( He, B; Li, C; Xing, C, 2020) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 5.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults." | 5.01 | Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. ( Hui, F; Li, X; Ren, T; Zhang, Y; Zhao, M; Zhao, Q, 2019) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 5.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| "For overweight polycystic ovary syndrome patients, our evidence revealed that EE/CA and EE/SRSP combined with metformin or lifestyle changes can reduce the adverse effects on glucose and lipid metabolism of the use of oral contraceptive agents alone." | 5.01 | The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. ( Li, Q; Liu, M; Mo, T; Shen, C; Wang, A, 2019) |
| "To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases." | 4.98 | The effects of metformin on simple obesity: a meta-analysis. ( Deng, B; Gao, PX; Le, J; Ning, HH; Qin, SL; Wang, Q; Young, CA; Zhang, HQ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 4.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| "English-language trials of benefits or harms of screening or treatment (behavior-based, orlistat, metformin) for overweight or obesity in children aged 2 through 18 years, conducted in or recruited from health care settings." | 4.95 | Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Burda, BU; Eder, M; Evans, CV; Lozano, P; O'Connor, EA; Walsh, ES, 2017) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 4.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 4.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| "The UK Prospective Diabetes Study showed that metformin decreases mortality compared to diet alone in overweight patients with type 2 diabetes mellitus." | 4.88 | Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. ( Bejan-Angoulvant, T; Boissel, JP; Boussageon, R; Cornu, C; Cucherat, M; Gueyffier, F; Kassai, B; Kellou, N; Moreau, A; Supper, I, 2012) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 4.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| " Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus." | 4.86 | The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. ( Ali, F; Dahmen, MM; Girrens, K; Khan, AY; Macaluso, M; McHale, RJ, 2010) |
| " Key words included adolescents, overweight, obesity, anti-obesity agents, drug therapy, orlistat, sibutramine, and metformin." | 4.84 | Pharmacotherapeutic options for overweight adolescents. ( Desilets, AR; Dunican, KC; Montalbano, JK, 2007) |
| "To evaluate the efficacy and safety of metformin for weight management in overweight and obese patients without type 2 diabetes." | 4.84 | Role of metformin for weight management in patients without type 2 diabetes. ( Desilets, AR; Dhakal-Karki, S; Dunican, KC, 2008) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 4.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| " The present study was purported to assess the effect of metformin and empagliflozin on MAO expression, oxidative stress and vascular reactivity in internal mammary arteries harvested from overweight patients with coronary heart disease subjected to bypass grafting." | 4.31 | Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries. ( Borza, C; Buriman, DG; Crețu, OM; Deaconu, L; Feier, HB; Ionică, LN; Lascu, A; Merce, AP; Muntean, DM; Sturza, A, 2023) |
| "The anti-diabetic drug metformin might reduce prevalence of chronic low back pain in people who are older, overweight, or less active." | 4.31 | The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. ( Carvalho-E-Silva, AP; Ferreira, ML; Ferreira, PH; Harmer, AR; Hartvigsen, J, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 4.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "Metformin is still being investigated due to its potential use as a therapeutic agent for managing overweight or obesity." | 4.12 | Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells. ( Cheng, Y; Deng, W; Du, B; Fang, D; Gao, Y; Jia, X; Lu, T; Wang, L; Yang, C; Yang, L; Zhai, Z, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 4.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 4.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 4.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 3.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 3.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " for their interest in our article on metformin and children with autism spectrum disorders (ASD) and for providing information about the MOBILITY study (a Patient-Centered Outcomes Research Institute (PCORI)-funded pragmatic clinical trial to examine the relative effectiveness of metformin plus healthy lifestyle instruction versus healthy lifestyle instruction alone)." | 3.88 | Dr. Handen et al. Reply. ( Aman, MG; Anagnostou, E; Handen, BL; Veenstra-VanderWeele, J, 2018) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 3.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 3.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 3.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 3.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| "To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients." | 3.81 | IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. ( Gong, WJ; Han, XY; Ji, LN; Li, X; Lin, X; Liu, RR; Liu, ZQ; Tang, Q; Xiao, D; Xu, XJ; Yin, JY; Zhang, SM; Zhang, W; Zheng, Y; Zhou, HH, 2015) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 3.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| "We examined the effects of therapy with metformin alone (n = 14) vs metformin with EP (n = 13) on HbA1C and lipid parameters over 10-14 months in 27 overweight girls, drawn from a clinic population of adolescents with PCOS." | 3.79 | Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. ( Bredella, MA; McManus, S; Misra, M, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 3.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 3.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS)." | 3.77 | Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. ( Fatemi, S; Morteza Taghavi, S; Rokni, H, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 3.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 3.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "7%) stopped metformin therapy due to excessive anorexia." | 3.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 3.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 3.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| " Obesity is the most important risk factor to develop this disease and metformin is considered as a first line drug in overweighted diabetic patients." | 3.73 | [Metformin in the treatment of type 2 diabetes in overweighted or obese patients]. ( Costa Zamora, P; Díaz, JM; González Alvaro, A; Martín Muñoz, MC; Muros Bayo, JM, 2005) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 3.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| "Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic." | 3.11 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. ( Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A, 2022) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 3.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| "Metformin treatment had a small but positive effect on bone quality in the peripheral skeleton, reduced weight gain, and resulted in a more beneficial body composition compared with placebo in insulin-treated patients with type 2 diabetes." | 3.01 | Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. ( Almdal, TP; Boesgaard, TW; Breum, L; Eiken, P; Gade-Rasmussen, B; Gluud, C; Hemmingsen, B; Lund, SS; Lundby-Christensen, L; Madsbad, S; Mathiesen, ER; Nordklint, AK; Perrild, H; Sneppen, SB; Tarnow, L; Thorsteinsson, B; Vestergaard, H; Vestergaard, P, 2021) |
| "In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents." | 2.87 | Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. ( Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG, 2018) |
| "For newly diagnosed Type 2 diabetes, some clinical features and laboratory parameters are important prognostic factors for predicting drug responsiveness." | 2.84 | Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial. ( Bao, Y; Han, J; Jia, W; Liu, F; Pang, J; Tu, Y; Yang, W; Yu, H, 2017) |
| "Identifying novel biomarkers of type 2 diabetes risk may improve prediction and prevention among individuals at high risk of the disease and elucidate new biological pathways relevant to diabetes development." | 2.82 | Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. ( Clish, C; Florez, JC; Gerszten, RE; Ma, Y; Walford, GA; Wang, TJ, 2016) |
| " The mean terminal half-life (t1/2 ) was 2-3 h." | 2.82 | Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ( Abribat, T; Allas, S; Delale, T; Julien, M; Ngo, N; Ritter, J; Sahakian, P; van der Lely, AJ, 2016) |
| "The dapagliflozin treatment arm was associated with a mean incremental benefit of 0." | 2.80 | The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. ( Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R, 2015) |
| "In people with Type 2 diabetes, empagliflozin 10 mg and 25 mg given as add-on to metformin for 76 weeks were well tolerated and led to sustained reductions in HbA1c , weight and systolic blood pressure." | 2.80 | Empagliflozin as add-on to metformin in people with Type 2 diabetes. ( Broedl, UC; Christiansen, AV; Häring, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ, 2015) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| "Approximately 2000 people with Type 2 diabetes mellitus who were drug-naive or who were treated with metformin for less than 1 month, and who have HbA1c of 48-58 mmol/mol (6." | 2.79 | Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. ( Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M, 2014) |
| "When treated with metformin and an exercise program, a structured, reduced energy diet, which is either high-carbohydrate or moderate-carbohydrate with increased-protein, can achieve clinically significant improvements in obese adolescents at risk of type 2 diabetes." | 2.79 | Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial. ( Ambler, GR; Baur, LA; Briody, J; Broderick, CR; Chisholm, K; Cowell, CT; De, S; Garnett, SP; Gow, M; Ho, M; Noakes, M; Srinivasan, S; Steinbeck, K; Woodhead, HJ, 2014) |
| " Primary endpoint was HbA1c, while secondary endpoints were body weight, frequency of hypoglycaemia, blood pressure, lipids, insulin dosage and self-monitored blood glucose profiles were measured." | 2.74 | The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. ( Beck-Nielsen, H; Henriksen, JE; Jacobsen, IB, 2009) |
| "Obesity has health consequences going beyond glucose elevation." | 2.72 | Pharmacotherapeutic options for prediabetes. ( Rendell, M, 2021) |
| " Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks." | 2.55 | Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Overweight and obesity are risk factors for type 2 diabetes, and they also influence the overall prognosis." | 2.49 | [Diabetes drugs and body weight]. ( Eriksson, J; Laine, M, 2013) |
| "With the rising prevalence of childhood obesity, pediatricians are increasingly called upon to treat clinically overweight children." | 2.49 | The clinical treatment of childhood obesity. ( Armstrong, SC; Dolinsky, DH; Kinra, S, 2013) |
| " Here, an adult physiologically based pharmacokinetic (PBPK) model of metformin was scaled to pediatric populations without obesity, with overweight/obesity, and with severe obesity; a published virtual population of children and adolescents with obesity was leveraged during model evaluation." | 1.72 | Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity. ( Edginton, AN; Ford, JL; Gerhart, JG; Gonzalez, D; Hon, YY; Yanovski, JA, 2022) |
| "Metformin was more often used in patients with obesity who also required higher daily doses." | 1.72 | Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus. ( Eder, A; Eppel, D; Geissler, F; Göbl, CS; Hösli, I; Huhn, EA; Linder, T; Monod, C; Redling, K; Rosicky, I, 2022) |
| "Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy." | 1.62 | Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. ( Brownfoot, F; Cannon, P; Cruickshank, T; Garcha, D; Hannan, NJ; Hyett, J; Illanes, SE; Jellins, J; Kaitu'u-Lino, TJ; Kandel, M; Keenan, E; MacDonald, TM; Masci, J; Middleton, A; Murphy, C; Murray, E; Myers, J; Nguyen, TV; Nien, JK; Pell, G; Pritchard, N; Roddy Mitchell, A; Schepeler, M; Tong, S; Walker, SP; Whigham, CA; Wong, GP, 2021) |
| "BE subjects developing esophageal cancer (EC) 12 months after their index BE diagnosis were defined as progressors." | 1.43 | Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. ( Borah, B; Chak, A; Das, A; Heien, H; Iyer, PG; Krishnamoorthi, R, 2016) |
| "Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients." | 1.43 | Diagnosis and Treatment of Polycystic Ovary Syndrome. ( Mortada, R; Porter, S; Williams, T, 2016) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Insulin resistance is a prevalent condition commonly associated with unhealthy lifestyles." | 1.42 | [Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance]. ( Araya, V; Arrese, M; Aylwin, CG; Bezanilla, CG; Carrasco, E; Carrasco, F; Codner, E; Díaz, E; Durruty, P; Galgani, J; García, H; Lahsen, R; Lanas, A; Liberman, C; López, G; Maíz, A; Mujica, V; Pollak, F; Poniachik, J; Sapunar, J; Sir, T; Soto, N; Valderas, J; Villaseca, P; Zavala, C, 2015) |
| "Metformin treatment increases serum cartonectin levels in these women and in omental AT explants." | 1.39 | Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. ( Adya, R; Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2013) |
| " The majority of the patients with type 2 diabetes of short duration did not meet any of the treatment goals as recommended in the current practice guidelines." | 1.39 | Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study. ( Bała, MM; Czupryniak, L; Jankowski, M; Leśniak, W; Michałejko, M; Płaczkiewicz-Jankowska, E; Sieradzki, J; Strzeszyński, L; Topór-Mądry, R, 2013) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 1.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| "(1) When type 2 diabetes is inadequately controlled with oral antidiabetic therapy, one option is to add subcutaneous insulin injections (or to accept less stringent glycaemic control)." | 1.34 | Exenatide: new drug. Type 2 diabetes for some overweight patients. ( , 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (15.66) | 29.6817 |
| 2010's | 126 (63.64) | 24.3611 |
| 2020's | 41 (20.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, RL | 1 |
| Deng, Y | 1 |
| Wang, YF | 1 |
| Zhu, SY | 1 |
| Ding, XS | 1 |
| Sun, AJ | 1 |
| Gao, L | 1 |
| Huang, H | 1 |
| Zhang, L | 1 |
| Zhang, N | 1 |
| Fu, Y | 1 |
| Zhu, D | 1 |
| Bi, Y | 1 |
| Feng, W | 1 |
| Zhao, YX | 1 |
| Wang, LJ | 1 |
| Gong, FY | 1 |
| Pan, H | 1 |
| Miao, H | 1 |
| Duan, L | 1 |
| Yang, HB | 1 |
| Zhu, HJ | 1 |
| Nwanaji-Enwerem, JC | 1 |
| Chung, FF | 1 |
| Van der Laan, L | 1 |
| Novoloaca, A | 1 |
| Cuenin, C | 1 |
| Johansson, H | 2 |
| Bonanni, B | 2 |
| Hubbard, AE | 1 |
| Smith, MT | 1 |
| Hartman, SJ | 4 |
| Cardenas, A | 1 |
| Sears, DD | 2 |
| Herceg, Z | 1 |
| Tracer, H | 1 |
| Mohnot, S | 1 |
| Green, CJ | 1 |
| Marjot, T | 1 |
| Walsby-Tickle, J | 1 |
| Charlton, C | 1 |
| Cornfield, T | 1 |
| Westcott, F | 1 |
| Pinnick, KE | 1 |
| Moolla, A | 1 |
| Hazlehurst, JM | 1 |
| McCullagh, J | 1 |
| Tomlinson, JW | 1 |
| Hodson, L | 1 |
| Bilusic, M | 1 |
| Toney, NJ | 1 |
| Donahue, RN | 1 |
| Wroblewski, S | 1 |
| Zibelman, M | 1 |
| Ghatalia, P | 1 |
| Ross, EA | 1 |
| Karzai, F | 1 |
| Madan, RA | 1 |
| Dahut, WL | 1 |
| Gulley, JL | 1 |
| Schlom, J | 1 |
| Plimack, ER | 1 |
| Geynisman, DM | 1 |
| Ford, JL | 1 |
| Gerhart, JG | 1 |
| Edginton, AN | 1 |
| Yanovski, JA | 1 |
| Hon, YY | 1 |
| Gonzalez, D | 1 |
| Ruan, G | 1 |
| Yuan, S | 1 |
| Lou, A | 1 |
| Mo, Y | 1 |
| Qu, Y | 1 |
| Guo, D | 1 |
| Guan, S | 1 |
| Zhang, Y | 5 |
| Lan, X | 1 |
| Luo, J | 1 |
| Mei, Y | 1 |
| Zhang, H | 1 |
| Wu, W | 1 |
| Dai, L | 1 |
| Yu, Q | 1 |
| Cai, X | 1 |
| Ding, C | 1 |
| Linder, T | 1 |
| Eder, A | 1 |
| Monod, C | 1 |
| Rosicky, I | 1 |
| Eppel, D | 1 |
| Redling, K | 1 |
| Geissler, F | 1 |
| Huhn, EA | 1 |
| Hösli, I | 1 |
| Göbl, CS | 1 |
| Yang, L | 1 |
| Jia, X | 1 |
| Fang, D | 1 |
| Cheng, Y | 1 |
| Zhai, Z | 1 |
| Deng, W | 1 |
| Du, B | 1 |
| Lu, T | 1 |
| Wang, L | 3 |
| Yang, C | 1 |
| Gao, Y | 1 |
| Li, R | 1 |
| Mai, T | 2 |
| Zheng, S | 2 |
| Wilson, C | 2 |
| Carpenter, J | 1 |
| Park, S | 1 |
| McHugh, C | 1 |
| Scott, EM | 1 |
| Hickie, IB | 1 |
| Xing, C | 3 |
| Zhao, H | 1 |
| Zhang, J | 2 |
| He, B | 3 |
| Bramante, CT | 1 |
| Huling, JD | 1 |
| Tignanelli, CJ | 1 |
| Buse, JB | 1 |
| Liebovitz, DM | 1 |
| Nicklas, JM | 1 |
| Cohen, K | 1 |
| Puskarich, MA | 1 |
| Belani, HK | 1 |
| Proper, JL | 1 |
| Siegel, LK | 1 |
| Klatt, NR | 1 |
| Odde, DJ | 1 |
| Luke, DG | 1 |
| Anderson, B | 1 |
| Karger, AB | 1 |
| Ingraham, NE | 1 |
| Hartman, KM | 1 |
| Rao, V | 1 |
| Hagen, AA | 1 |
| Patel, B | 1 |
| Fenno, SL | 1 |
| Avula, N | 1 |
| Reddy, NV | 1 |
| Erickson, SM | 1 |
| Lindberg, S | 1 |
| Fricton, R | 1 |
| Lee, S | 1 |
| Zaman, A | 1 |
| Saveraid, HG | 1 |
| Tordsen, WJ | 1 |
| Pullen, MF | 1 |
| Biros, M | 1 |
| Sherwood, NE | 1 |
| Thompson, JL | 1 |
| Boulware, DR | 1 |
| Murray, TA | 1 |
| Deussen, AR | 2 |
| Louise, J | 2 |
| Dodd, JM | 2 |
| Cheng, X | 1 |
| Azócar-Gallardo, J | 1 |
| Ramirez-Campillo, R | 1 |
| Afonso, J | 1 |
| Sá, M | 1 |
| Granacher, U | 1 |
| González-Rojas, L | 1 |
| Ojeda-Aravena, A | 1 |
| García-García, JM | 1 |
| Bianzano, S | 2 |
| Nordaby, M | 2 |
| Plum-Mörschel, L | 2 |
| Peil, B | 2 |
| Heise, T | 2 |
| El-Attar, AA | 1 |
| Ibrahim, OM | 1 |
| Alhassanin, SA | 1 |
| Essa, ES | 1 |
| Mostafa, TM | 1 |
| Bellerba, F | 1 |
| Chatziioannou, AC | 1 |
| Jasbi, P | 1 |
| Robinot, N | 1 |
| Keski-Rahkonen, P | 1 |
| Trolat, A | 1 |
| Vozar, B | 1 |
| Scalbert, A | 1 |
| Gandini, S | 1 |
| Lascu, A | 1 |
| Ionică, LN | 1 |
| Buriman, DG | 1 |
| Merce, AP | 1 |
| Deaconu, L | 1 |
| Borza, C | 1 |
| Crețu, OM | 1 |
| Sturza, A | 1 |
| Muntean, DM | 1 |
| Feier, HB | 1 |
| Cai, H | 1 |
| Chen, Q | 1 |
| Duan, Y | 1 |
| Zhao, Y | 1 |
| Zhang, X | 1 |
| Carvalho-E-Silva, AP | 1 |
| Ferreira, PH | 1 |
| Harmer, AR | 1 |
| Hartvigsen, J | 1 |
| Ferreira, ML | 1 |
| Poh Shean, W | 1 |
| Chin Voon, T | 1 |
| Long Bidin, MBB | 1 |
| Adam, NLB | 1 |
| Velazquez, C | 1 |
| Herrero, Y | 1 |
| Bianchi, MS | 1 |
| Cohen, DJ | 1 |
| Cuasnicu, P | 1 |
| Prost, K | 1 |
| Marinoni, R | 1 |
| Pascuali, N | 1 |
| Parborell, F | 1 |
| Abramovich, D | 1 |
| Bahat, G | 1 |
| Ozkok, S | 1 |
| Petrovic, M | 1 |
| Małecki, MT | 1 |
| Batterham, RL | 1 |
| Sattar, N | 1 |
| Levine, JA | 1 |
| Rodríguez, Á | 1 |
| Bergman, BK | 1 |
| Wang, H | 3 |
| Ghimpeteanu, G | 1 |
| Lee, CJ | 1 |
| Bettencourt-Silva, R | 1 |
| Neves, JS | 1 |
| Ferreira, MJ | 1 |
| Souteiro, P | 1 |
| Belo, S | 1 |
| Oliveira, AI | 1 |
| Carvalho, D | 1 |
| Namora, G | 1 |
| Montenegro, N | 1 |
| Queirós, J | 1 |
| Ortega, JF | 1 |
| Morales-Palomo, F | 1 |
| Ramirez-Jimenez, M | 1 |
| Moreno-Cabañas, A | 1 |
| Mora-Rodríguez, R | 1 |
| Elkind-Hirsch, KE | 2 |
| Shaler, D | 1 |
| Harris, R | 2 |
| Li, C | 1 |
| Papaetis, GS | 1 |
| Filippou, PK | 1 |
| Constantinidou, KG | 1 |
| Stylianou, CS | 1 |
| Rendell, M | 1 |
| Muskiet, MHA | 1 |
| Tonneijck, L | 1 |
| Smits, MM | 1 |
| Kramer, MHH | 1 |
| Ouwens, DM | 1 |
| Hartmann, B | 1 |
| Holst, JJ | 1 |
| Touw, DJ | 1 |
| Danser, AHJ | 1 |
| Joles, JA | 1 |
| van Raalte, DH | 1 |
| Tao, T | 2 |
| Zhu, YC | 1 |
| Fu, JR | 1 |
| Wang, YY | 1 |
| Cai, J | 1 |
| Ma, JY | 1 |
| Xu, Y | 1 |
| Gao, YN | 1 |
| Sun, Y | 1 |
| Fan, W | 1 |
| Liu, W | 2 |
| Færch, K | 1 |
| Blond, MB | 1 |
| Bruhn, L | 1 |
| Amadid, H | 1 |
| Vistisen, D | 1 |
| Clemmensen, KKB | 1 |
| Vainø, CTR | 1 |
| Pedersen, C | 1 |
| Tvermosegaard, M | 1 |
| Dejgaard, TF | 1 |
| Karstoft, K | 1 |
| Ried-Larsen, M | 1 |
| Persson, F | 1 |
| Jørgensen, ME | 1 |
| Seidemann, E | 1 |
| Nordklint, AK | 1 |
| Almdal, TP | 1 |
| Vestergaard, P | 1 |
| Lundby-Christensen, L | 1 |
| Boesgaard, TW | 1 |
| Breum, L | 1 |
| Gade-Rasmussen, B | 1 |
| Sneppen, SB | 1 |
| Gluud, C | 1 |
| Hemmingsen, B | 1 |
| Perrild, H | 1 |
| Madsbad, S | 2 |
| Mathiesen, ER | 1 |
| Tarnow, L | 1 |
| Thorsteinsson, B | 1 |
| Vestergaard, H | 1 |
| Lund, SS | 1 |
| Eiken, P | 1 |
| Li, X | 3 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 1 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Janani, L | 1 |
| Bamehr, H | 1 |
| Tanha, K | 1 |
| Mirzabeigi, P | 1 |
| Montazeri, H | 1 |
| Tarighi, P | 1 |
| Garcha, D | 1 |
| Walker, SP | 1 |
| MacDonald, TM | 1 |
| Hyett, J | 1 |
| Jellins, J | 1 |
| Myers, J | 1 |
| Illanes, SE | 1 |
| Nien, JK | 1 |
| Schepeler, M | 1 |
| Keenan, E | 1 |
| Whigham, CA | 1 |
| Cannon, P | 1 |
| Murray, E | 1 |
| Nguyen, TV | 1 |
| Kandel, M | 1 |
| Masci, J | 1 |
| Murphy, C | 1 |
| Cruickshank, T | 1 |
| Pritchard, N | 1 |
| Hannan, NJ | 1 |
| Brownfoot, F | 1 |
| Roddy Mitchell, A | 1 |
| Middleton, A | 1 |
| Pell, G | 1 |
| Wong, GP | 1 |
| Tong, S | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Wink, LK | 1 |
| Adams, R | 1 |
| Pedapati, EV | 1 |
| Dominick, KC | 1 |
| Fox, E | 1 |
| Buck, C | 1 |
| Erickson, CA | 1 |
| Viskochil, R | 1 |
| Malin, SK | 1 |
| Blankenship, JM | 1 |
| Braun, B | 1 |
| O'Connor, EA | 1 |
| Evans, CV | 1 |
| Burda, BU | 1 |
| Walsh, ES | 1 |
| Eder, M | 1 |
| Lozano, P | 1 |
| Lingvay, I | 1 |
| Harris, S | 1 |
| Jaeckel, E | 1 |
| Chandarana, K | 1 |
| Ranthe, MF | 1 |
| Jódar, E | 1 |
| Wang, Z | 1 |
| Sun, J | 1 |
| Han, R | 1 |
| Fan, D | 1 |
| Dong, X | 1 |
| Luan, Z | 1 |
| Xiang, R | 1 |
| Zhao, M | 2 |
| Yang, J | 1 |
| Out, M | 2 |
| Miedema, I | 1 |
| Jager-Wittenaar, H | 1 |
| van der Schans, C | 1 |
| Krijnen, W | 1 |
| Lehert, P | 2 |
| Stehouwer, C | 1 |
| Kooy, A | 3 |
| Perreault, L | 3 |
| Pan, Q | 2 |
| Aroda, VR | 2 |
| Barrett-Connor, E | 6 |
| Dabelea, D | 1 |
| Dagogo-Jack, S | 1 |
| Hamman, RF | 3 |
| Kahn, SE | 2 |
| Mather, KJ | 4 |
| Knowler, WC | 5 |
| Nielsen, SM | 1 |
| Bartels, EM | 1 |
| Henriksen, M | 1 |
| Wæhrens, EE | 1 |
| Gudbergsen, H | 1 |
| Bliddal, H | 1 |
| Astrup, A | 1 |
| Knop, FK | 1 |
| Carmona, L | 1 |
| Taylor, WJ | 1 |
| Singh, JA | 1 |
| Perez-Ruiz, F | 1 |
| Kristensen, LE | 1 |
| Christensen, R | 1 |
| Walkup, JT | 2 |
| Cottingham, E | 2 |
| Handen, BL | 4 |
| Anagnostou, E | 3 |
| Aman, MG | 4 |
| Sanders, KB | 3 |
| Chan, J | 2 |
| Hollway, JA | 3 |
| Brian, J | 2 |
| Arnold, LE | 3 |
| Capano, L | 2 |
| Williams, C | 1 |
| Hellings, JA | 2 |
| Butter, E | 2 |
| Mankad, D | 2 |
| Tumuluru, R | 2 |
| Kettel, J | 2 |
| Newsom, CR | 2 |
| Peleg, N | 3 |
| Odrobina, D | 2 |
| McAuliffe-Bellin, S | 2 |
| Marler, S | 3 |
| Wong, T | 3 |
| Wagner, A | 2 |
| Hadjiyannakis, S | 2 |
| Macklin, EA | 2 |
| Veenstra-VanderWeele, J | 4 |
| Herman, WH | 1 |
| Edelstein, SL | 3 |
| Dabelea, DM | 1 |
| Horton, E | 2 |
| Lorenzo, C | 1 |
| Pi-Sunyer, X | 3 |
| Venditti, E | 2 |
| Ye, W | 1 |
| Song, J | 2 |
| Ruan, X | 2 |
| Gu, M | 2 |
| Mueck, AO | 2 |
| Pratley, RE | 1 |
| Eldor, R | 1 |
| Raji, A | 1 |
| Golm, G | 1 |
| Huyck, SB | 1 |
| Qiu, Y | 1 |
| Sunga, S | 1 |
| Johnson, J | 1 |
| Terra, SG | 1 |
| Mancuso, JP | 1 |
| Engel, SS | 1 |
| Lauring, B | 1 |
| Alves Ferreira, M | 1 |
| Oliveira Gomes, AP | 1 |
| Guimarães de Moraes, AP | 1 |
| Ferreira Stringhini, ML | 1 |
| Mota, JF | 1 |
| Siqueira Guedes Coelho, A | 1 |
| Borges Botelho, P | 1 |
| Hanem, LGE | 2 |
| Stridsklev, S | 1 |
| Júlíusson, PB | 1 |
| Salvesen, Ø | 1 |
| Roelants, M | 1 |
| Carlsen, SM | 1 |
| Ødegård, R | 2 |
| Vanky, E | 2 |
| Greenhill, C | 1 |
| Abdalmageed, OS | 1 |
| Farghaly, TA | 1 |
| Abdelaleem, AA | 1 |
| Abdelmagied, AE | 1 |
| Ali, MK | 2 |
| Abbas, AM | 1 |
| Macklin, E | 1 |
| Newsom, C | 1 |
| Hastie Adams, R | 1 |
| Anagnostou, EA | 1 |
| Top, WMC | 1 |
| Schalkwijk, CA | 1 |
| Stehouwer, CDA | 1 |
| Nicodemus, NA | 1 |
| Castillo-Castro, C | 1 |
| Gonzalez-Velazquez, C | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Júnior, VC | 1 |
| Fuchs, FD | 1 |
| Schaan, BD | 1 |
| Moreira, LB | 1 |
| Fuchs, SC | 1 |
| Gus, M | 1 |
| Ning, HH | 1 |
| Le, J | 1 |
| Wang, Q | 1 |
| Young, CA | 1 |
| Deng, B | 1 |
| Gao, PX | 1 |
| Zhang, HQ | 1 |
| Qin, SL | 1 |
| Higdon, C | 1 |
| Correll, CU | 1 |
| Crystal, S | 1 |
| Patel, N | 1 |
| DelBello, MP | 1 |
| Lentferink, YE | 1 |
| Knibbe, CAJ | 1 |
| van der Vorst, MMJ | 1 |
| Hui, F | 1 |
| Ren, T | 1 |
| Zhao, Q | 1 |
| Grivell, RM | 1 |
| Dekker, G | 1 |
| McPhee, AJ | 1 |
| Hague, W | 1 |
| Catalano, PM | 1 |
| He, X | 1 |
| Wu, D | 1 |
| Hu, C | 1 |
| Xu, T | 1 |
| Liu, Y | 2 |
| Liu, C | 1 |
| Xu, B | 1 |
| Tang, W | 1 |
| Yam, C | 1 |
| Esteva, FJ | 2 |
| Patel, MM | 1 |
| Raghavendra, AS | 1 |
| Ueno, NT | 1 |
| Moulder, SL | 2 |
| Hess, KR | 1 |
| Shroff, GS | 1 |
| Hodge, S | 1 |
| Koenig, KH | 1 |
| Chavez Mac Gregor, M | 1 |
| Griner, RL | 1 |
| Yeung, SJ | 1 |
| Hortobagyi, GN | 2 |
| Valero, V | 1 |
| D'Onofrio, N | 1 |
| Pieretti, G | 1 |
| Ciccarelli, F | 1 |
| Gambardella, A | 1 |
| Passariello, N | 1 |
| Rizzo, MR | 1 |
| Barbieri, M | 1 |
| Marfella, R | 1 |
| Nicoletti, G | 1 |
| Balestrieri, ML | 1 |
| Sardu, C | 1 |
| Wang, A | 2 |
| Mo, T | 1 |
| Li, Q | 1 |
| Shen, C | 1 |
| Liu, M | 1 |
| Liu, E | 1 |
| Long, T | 1 |
| Liu, X | 1 |
| Gong, Y | 1 |
| Shen, H | 1 |
| Chen, H | 1 |
| Lin, R | 1 |
| Zheng, Y | 2 |
| Xie, Y | 1 |
| Wang, F | 1 |
| Morotti, E | 1 |
| Giovanni Artini, P | 1 |
| Persico, N | 1 |
| Battaglia, C | 1 |
| Nelson, SH | 1 |
| Marinac, CR | 2 |
| Natarajan, L | 2 |
| Parker, BA | 1 |
| Patterson, RE | 2 |
| Eriksson, J | 1 |
| Laine, M | 1 |
| Ravn, P | 1 |
| Haugen, AG | 1 |
| Glintborg, D | 1 |
| Garnett, SP | 2 |
| Gow, M | 2 |
| Ho, M | 2 |
| Baur, LA | 2 |
| Noakes, M | 3 |
| Woodhead, HJ | 2 |
| Broderick, CR | 2 |
| Burrell, S | 1 |
| Chisholm, K | 2 |
| Halim, J | 1 |
| De, S | 2 |
| Steinbeck, K | 2 |
| Srinivasan, S | 2 |
| Ambler, GR | 2 |
| Kohn, MR | 1 |
| Cowell, CT | 2 |
| Kim, C | 4 |
| Stentz, FB | 1 |
| Murphy, MB | 1 |
| Kong, S | 3 |
| Nan, B | 3 |
| Kitabchi, AE | 1 |
| Chen, CH | 1 |
| Huang, MC | 1 |
| Kao, CF | 1 |
| Lin, SK | 1 |
| Kuo, PH | 1 |
| Chiu, CC | 1 |
| Lu, ML | 1 |
| Randolph, JF | 2 |
| Golden, SH | 3 |
| Morgante, G | 1 |
| Musacchio, MC | 1 |
| Orvieto, R | 1 |
| Massaro, MG | 1 |
| De Leo, V | 1 |
| Ghotbi, AA | 1 |
| Køber, L | 1 |
| Finer, N | 1 |
| James, WP | 1 |
| Sharma, AM | 1 |
| Caterson, I | 1 |
| Coutinho, W | 1 |
| Van Gaal, LF | 1 |
| Torp-Pedersen, C | 1 |
| Andersson, C | 1 |
| Tan, BK | 2 |
| Chen, J | 3 |
| Hu, J | 1 |
| Amar, O | 1 |
| Mattu, HS | 1 |
| Adya, R | 2 |
| Patel, V | 1 |
| Ramanjaneya, M | 1 |
| Lehnert, H | 2 |
| Randeva, HS | 2 |
| Checkley, LA | 1 |
| Rho, O | 1 |
| Angel, JM | 1 |
| Cho, J | 1 |
| Blando, J | 1 |
| Beltran, L | 1 |
| Hursting, SD | 1 |
| DiGiovanni, J | 1 |
| Bała, MM | 1 |
| Płaczkiewicz-Jankowska, E | 1 |
| Leśniak, W | 1 |
| Topór-Mądry, R | 1 |
| Michałejko, M | 1 |
| Jankowski, M | 1 |
| Strzeszyński, L | 1 |
| Sieradzki, J | 1 |
| Czupryniak, L | 1 |
| Kalinsky, K | 1 |
| Crew, KD | 1 |
| Refice, S | 1 |
| Xiao, T | 1 |
| Feldman, SM | 1 |
| Taback, B | 1 |
| Ahmad, A | 1 |
| Cremers, S | 1 |
| Hibshoosh, H | 1 |
| Maurer, M | 1 |
| Hershman, DL | 1 |
| Raccah, D | 1 |
| Gourdy, P | 1 |
| Sagnard, L | 1 |
| Ceriello, A | 1 |
| Skrivanek, Z | 1 |
| Gaydos, BL | 1 |
| Chien, JY | 1 |
| Geiger, MJ | 1 |
| Heathman, MA | 1 |
| Berry, S | 1 |
| Anderson, JH | 1 |
| Forst, T | 1 |
| Milicevic, Z | 1 |
| Berry, D | 1 |
| Ma, J | 1 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Del Prato, S | 1 |
| Foley, JE | 1 |
| Kothny, W | 1 |
| Kozlovski, P | 1 |
| Stumvoll, M | 1 |
| Paldánius, PM | 1 |
| Matthews, DR | 1 |
| Konrad, K | 1 |
| Datz, N | 1 |
| Engelsberger, I | 1 |
| Grulich-Henn, J | 1 |
| Hoertenhuber, T | 1 |
| Knauth, B | 1 |
| Meissner, T | 1 |
| Wiegand, S | 1 |
| Woelfle, J | 1 |
| Holl, RW | 1 |
| Stokes, VJ | 1 |
| Anderson, RA | 1 |
| George, JT | 1 |
| Labrie, F | 2 |
| Kurzthaler, D | 1 |
| Hadziomerovic-Pekic, D | 1 |
| Wildt, L | 1 |
| Seeber, BE | 1 |
| Briody, J | 1 |
| Shafiee, MN | 1 |
| Malik, DA | 1 |
| Yunos, RI | 1 |
| Atiomo, W | 1 |
| Omar, MH | 1 |
| Ghani, NA | 1 |
| Hatta, AZ | 1 |
| Seedhouse, C | 1 |
| Chapman, C | 1 |
| Mokhtar, NM | 1 |
| Li, M | 1 |
| Yang, M | 1 |
| Zhou, X | 1 |
| Fang, X | 1 |
| Hu, W | 1 |
| Zhu, W | 1 |
| Wang, C | 1 |
| Liu, D | 2 |
| Li, S | 1 |
| Liu, H | 1 |
| Yang, G | 2 |
| Li, L | 1 |
| Irving, BA | 1 |
| Carter, RE | 1 |
| Soop, M | 1 |
| Weymiller, A | 1 |
| Syed, H | 1 |
| Karakelides, H | 1 |
| Bhagra, S | 1 |
| Short, KR | 1 |
| Tatpati, L | 1 |
| Barazzoni, R | 1 |
| Nair, KS | 1 |
| Tanaka, K | 2 |
| Saisho, Y | 2 |
| Kawai, T | 2 |
| Tanaka, M | 2 |
| Meguro, S | 2 |
| Irie, J | 2 |
| Imai, T | 1 |
| Shigihara, T | 1 |
| Morimoto, J | 1 |
| Yajima, K | 1 |
| Atsumi, Y | 1 |
| Takei, I | 1 |
| Itoh, H | 2 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Charokopou, M | 1 |
| McEwan, P | 1 |
| Lister, S | 1 |
| Callan, L | 1 |
| Bergenheim, K | 1 |
| Tolley, K | 1 |
| Postema, R | 1 |
| Townsend, R | 1 |
| Roudaut, M | 1 |
| Simmons, D | 1 |
| Merker, L | 1 |
| Häring, HU | 1 |
| Christiansen, AV | 1 |
| Roux, F | 1 |
| Salsali, A | 1 |
| Kim, G | 1 |
| Meinicke, T | 1 |
| Woerle, HJ | 1 |
| Broedl, UC | 1 |
| Kharroubi, AT | 1 |
| Darwish, HM | 1 |
| Akkawi, MA | 1 |
| Ashareef, AA | 1 |
| Almasri, ZA | 1 |
| Bader, KA | 1 |
| Khammash, UM | 1 |
| Pollak, F | 1 |
| Araya, V | 1 |
| Lanas, A | 1 |
| Sapunar, J | 1 |
| Arrese, M | 1 |
| Aylwin, CG | 1 |
| Bezanilla, CG | 1 |
| Carrasco, E | 1 |
| Carrasco, F | 1 |
| Codner, E | 1 |
| Díaz, E | 1 |
| Durruty, P | 1 |
| Galgani, J | 1 |
| García, H | 1 |
| Lahsen, R | 1 |
| Liberman, C | 1 |
| López, G | 1 |
| Maíz, A | 1 |
| Mujica, V | 1 |
| Poniachik, J | 1 |
| Sir, T | 1 |
| Soto, N | 1 |
| Valderas, J | 1 |
| Villaseca, P | 1 |
| Zavala, C | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Manesso, E | 1 |
| Sugiura, H | 1 |
| Jinzaki, M | 1 |
| Cobelli, C | 1 |
| Cheng, F | 1 |
| Zhao, L | 1 |
| Wu, Y | 2 |
| Huang, T | 1 |
| Zhang, Z | 1 |
| Jia, F | 1 |
| Wu, J | 1 |
| Chen, C | 1 |
| Xiao, D | 1 |
| Zhang, SM | 1 |
| Yin, JY | 1 |
| Gong, WJ | 1 |
| Xu, XJ | 1 |
| Lin, X | 1 |
| Ji, LN | 1 |
| Liu, RR | 1 |
| Tang, Q | 1 |
| Zhang, W | 1 |
| Zhou, HH | 1 |
| Han, XY | 1 |
| Liu, ZQ | 1 |
| Ertefaie, A | 1 |
| Small, D | 1 |
| Flory, J | 1 |
| Hennessy, S | 1 |
| Cadmus-Bertram, L | 1 |
| Flatt, SW | 1 |
| Li, H | 1 |
| Parker, B | 1 |
| Oratowski-Coleman, J | 1 |
| Villaseñor, A | 1 |
| Godbole, S | 1 |
| Kerr, J | 1 |
| Krishnamoorthi, R | 1 |
| Borah, B | 1 |
| Heien, H | 1 |
| Das, A | 1 |
| Chak, A | 1 |
| Iyer, PG | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Walford, GA | 1 |
| Ma, Y | 2 |
| Clish, C | 1 |
| Florez, JC | 1 |
| Wang, TJ | 1 |
| Gerszten, RE | 1 |
| Luchsinger, JA | 1 |
| Perez, T | 1 |
| Chang, H | 1 |
| Mehta, P | 1 |
| Steffener, J | 1 |
| Pradabhan, G | 1 |
| Ichise, M | 1 |
| Manly, J | 1 |
| Devanand, DP | 1 |
| Bagiella, E | 1 |
| Amouyal, C | 1 |
| Andreelli, F | 1 |
| Sun, W | 1 |
| Zeng, C | 1 |
| Liao, L | 1 |
| Wang, Y | 1 |
| Allas, S | 1 |
| Delale, T | 1 |
| Ngo, N | 1 |
| Julien, M | 1 |
| Sahakian, P | 1 |
| Ritter, J | 1 |
| Abribat, T | 1 |
| van der Lely, AJ | 1 |
| Goldberg, RB | 1 |
| Temprosa, M | 1 |
| Mele, L | 1 |
| Orchard, T | 1 |
| Mather, K | 1 |
| Bray, G | 1 |
| Kitabchi, A | 1 |
| Krakoff, J | 2 |
| Marcovina, S | 1 |
| White, N | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Hao, Z | 1 |
| Liao, H | 1 |
| Zheng, D | 1 |
| Xiao, C | 1 |
| Li, G | 1 |
| Ou, HT | 1 |
| Chen, PC | 1 |
| Wu, MH | 1 |
| Han, J | 2 |
| Yu, H | 1 |
| Tu, Y | 1 |
| Pang, J | 1 |
| Liu, F | 1 |
| Bao, Y | 1 |
| Yang, W | 1 |
| Jia, W | 1 |
| Birch Petersen, K | 1 |
| Pedersen, NG | 1 |
| Pedersen, AT | 1 |
| Lauritsen, MP | 1 |
| la Cour Freiesleben, N | 1 |
| Rosenstock, J | 1 |
| Guerci, B | 1 |
| Hanefeld, M | 1 |
| Gentile, S | 1 |
| Aronson, R | 1 |
| Tinahones, FJ | 1 |
| Roy-Duval, C | 1 |
| Souhami, E | 1 |
| Wardecki, M | 1 |
| Ye, J | 1 |
| Perfetti, R | 1 |
| Heller, S | 1 |
| Christophi, CA | 2 |
| Horton, ES | 1 |
| Bray, GA | 2 |
| Williams, T | 1 |
| Mortada, R | 1 |
| Porter, S | 1 |
| Weber, MB | 1 |
| Ranjani, H | 1 |
| Staimez, LR | 1 |
| Anjana, RM | 1 |
| Narayan, KM | 1 |
| Mohan, V | 1 |
| Shui, A | 1 |
| Zakroysky, P | 1 |
| Kumarathurai, P | 1 |
| Anholm, C | 1 |
| Larsen, BS | 1 |
| Olsen, RH | 1 |
| Kristiansen, O | 1 |
| Nielsen, OW | 1 |
| Haugaard, SB | 1 |
| Sajadieh, A | 1 |
| Maurizi, AR | 1 |
| Menduni, M | 1 |
| Del Toro, R | 1 |
| Kyanvash, S | 1 |
| Maggi, D | 1 |
| Guglielmi, C | 1 |
| Pantano, AL | 1 |
| Defeudis, G | 1 |
| Fioriti, E | 1 |
| Manfrini, S | 1 |
| Pozzilli, P | 1 |
| Al Khalifah, RA | 1 |
| Alnhdi, A | 1 |
| Alghar, H | 1 |
| Alanazi, M | 1 |
| Florez, ID | 1 |
| Al-Oanzi, ZH | 1 |
| Fountana, S | 1 |
| Moonira, T | 1 |
| Tudhope, SJ | 1 |
| Petrie, JL | 1 |
| Alshawi, A | 1 |
| Patman, G | 1 |
| Arden, C | 1 |
| Reeves, HL | 1 |
| Agius, L | 1 |
| Venditti, EM | 1 |
| Carrion-Petersen, ML | 1 |
| Delahanty, LM | 1 |
| Hoskin, MA | 1 |
| Andreadis, EA | 1 |
| Katsanou, PM | 1 |
| Georgiopoulos, DX | 1 |
| Tsourous, GI | 1 |
| Yfanti, GK | 1 |
| Gouveri, ET | 1 |
| Diamantopoulos, EJ | 1 |
| Helvaci, MR | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Yalcin, A | 1 |
| Jacobsen, IB | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Moran, LJ | 1 |
| Meyer, C | 3 |
| Hutchison, SK | 2 |
| Zoungas, S | 1 |
| Teede, HJ | 3 |
| Heller, SR | 1 |
| Fowler, SE | 1 |
| Hoffman, HJ | 1 |
| Brenneman, AT | 1 |
| Brown-Friday, JO | 1 |
| Goldberg, R | 1 |
| Nathan, DM | 1 |
| Lim, SS | 1 |
| Norman, RJ | 1 |
| Clifton, PM | 1 |
| Clark, JM | 1 |
| Crandall, JP | 1 |
| Molitch, ME | 1 |
| Brancati, FL | 1 |
| Winsberg, B | 1 |
| Yeager, C | 1 |
| Hobbs, B | 1 |
| Wei, R | 1 |
| Elangovan, N | 1 |
| Marsh, KA | 1 |
| Steinbeck, KS | 1 |
| Atkinson, FS | 1 |
| Petocz, P | 1 |
| Brand-Miller, JC | 1 |
| Genazzani, AD | 1 |
| Chierchia, E | 1 |
| Rattighieri, E | 1 |
| Santagni, S | 1 |
| Casarosa, E | 1 |
| Luisi, M | 1 |
| Genazzani, AR | 1 |
| Khan, AY | 1 |
| Macaluso, M | 1 |
| McHale, RJ | 1 |
| Dahmen, MM | 1 |
| Girrens, K | 1 |
| Ali, F | 1 |
| Morteza Taghavi, S | 1 |
| Rokni, H | 1 |
| Fatemi, S | 1 |
| Praharaj, SK | 1 |
| Jana, AK | 1 |
| Goyal, N | 1 |
| Sinha, VK | 1 |
| Koiou, E | 2 |
| Tziomalos, K | 2 |
| Dinas, K | 1 |
| Katsikis, I | 2 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Panidis, D | 2 |
| Gangale, MF | 1 |
| Miele, L | 1 |
| Lanzone, A | 1 |
| Sagnella, F | 1 |
| Martinez, D | 1 |
| Tropea, A | 1 |
| Moro, F | 1 |
| Morciano, A | 1 |
| Ciardulli, A | 1 |
| Palla, C | 1 |
| Pompili, M | 1 |
| Cefalo, C | 1 |
| Grieco, A | 1 |
| Apa, R | 1 |
| Essah, PA | 1 |
| Arrowood, JA | 1 |
| Cheang, KI | 1 |
| Adawadkar, SS | 1 |
| Stovall, DW | 1 |
| Nestler, JE | 1 |
| Vosnakis, C | 1 |
| Newall, H | 1 |
| Myles, N | 1 |
| Ward, PB | 1 |
| Samaras, K | 1 |
| Shiers, D | 1 |
| Curtis, J | 1 |
| Le Donne, M | 1 |
| Alibrandi, A | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Wang, M | 1 |
| Tong, JH | 1 |
| Zhu, G | 1 |
| Liang, GM | 1 |
| Yan, HF | 1 |
| Wang, XZ | 1 |
| Rajagopal, G | 1 |
| Reddy, AP | 1 |
| Venkata Harinarayan, C | 1 |
| Suresh, V | 1 |
| Bitla, A | 1 |
| P V L N Rao, S | 1 |
| Sachan, A | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Boussageon, R | 1 |
| Supper, I | 1 |
| Bejan-Angoulvant, T | 1 |
| Kellou, N | 1 |
| Cucherat, M | 1 |
| Boissel, JP | 1 |
| Kassai, B | 1 |
| Moreau, A | 1 |
| Gueyffier, F | 1 |
| Cornu, C | 1 |
| Dolinsky, DH | 1 |
| Armstrong, SC | 1 |
| Kinra, S | 1 |
| Bredella, MA | 1 |
| McManus, S | 1 |
| Misra, M | 1 |
| Fradkin, JE | 1 |
| Roberts, BT | 1 |
| Rodgers, GP | 1 |
| Gonzalez-Angulo, AM | 1 |
| Ensor, J | 1 |
| Murray, JL | 1 |
| Green, MC | 1 |
| Koenig, KB | 1 |
| Lee, MH | 1 |
| Yeung, SC | 1 |
| Bouza, C | 1 |
| López-Cuadrado, T | 1 |
| Gutierrez-Torres, LF | 1 |
| Amate, J | 1 |
| Mohsen, IA | 1 |
| Elkattan, E | 1 |
| Nabil, H | 1 |
| Khattab, S | 1 |
| Esfahanian, F | 1 |
| Zamani, MM | 1 |
| Heshmat, R | 1 |
| Moini nia, F | 1 |
| Brännmark, C | 1 |
| Nyman, E | 1 |
| Fagerholm, S | 1 |
| Bergenholm, L | 1 |
| Ekstrand, EM | 1 |
| Cedersund, G | 1 |
| Strålfors, P | 1 |
| Fernández Fernández, I | 1 |
| Martín Muñoz, MC | 1 |
| Díaz, JM | 1 |
| Muros Bayo, JM | 1 |
| González Alvaro, A | 1 |
| Costa Zamora, P | 1 |
| Ratner, RE | 1 |
| Maggs, D | 1 |
| Nielsen, LL | 1 |
| Stonehouse, AH | 1 |
| Poon, T | 1 |
| Zhang, B | 2 |
| Bicsak, TA | 1 |
| Brodows, RG | 1 |
| Kim, DD | 2 |
| Blonde, L | 1 |
| Klein, EJ | 1 |
| Mac, SM | 1 |
| Poon, TH | 1 |
| Taylor, KL | 1 |
| Trautmann, ME | 1 |
| Kendall, DM | 1 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
| Khan, AS | 1 |
| McLoughney, CR | 1 |
| Ahmed, AB | 1 |
| McGrath, BP | 1 |
| Lóriz Peralta, O | 1 |
| Campos Bonilla, B | 1 |
| Granada Ybern, ML | 1 |
| Sanmartí Sala, A | 1 |
| Arroyo Bros, J | 1 |
| Balen, AH | 1 |
| Dunican, KC | 2 |
| Desilets, AR | 2 |
| Montalbano, JK | 1 |
| Tamura, Y | 1 |
| Watada, H | 1 |
| Sato, F | 1 |
| Kumashiro, N | 1 |
| Sakurai, Y | 1 |
| Hirose, T | 1 |
| Tanaka, Y | 1 |
| Kawamori, R | 1 |
| Tan, S | 1 |
| Hahn, S | 1 |
| Benson, S | 1 |
| Dietz, T | 1 |
| Lahner, H | 1 |
| Moeller, LC | 1 |
| Schmidt, M | 1 |
| Elsenbruch, S | 1 |
| Kimmig, R | 1 |
| Mann, K | 1 |
| Janssen, OE | 1 |
| Wu, RR | 1 |
| Zhao, JP | 1 |
| Jin, H | 1 |
| Shao, P | 1 |
| Fang, MS | 1 |
| Guo, XF | 1 |
| He, YQ | 1 |
| Liu, YJ | 1 |
| Chen, JD | 1 |
| Li, LH | 1 |
| Hexeberg, S | 1 |
| Lindberg, FA | 1 |
| Tessari, P | 1 |
| Tiengo, A | 1 |
| Derosa, G | 1 |
| Salvadeo, SA | 1 |
| D'Angelo, A | 1 |
| Fogari, E | 1 |
| Ragonesi, PD | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Maffioli, P | 1 |
| Cicero, AF | 1 |
| Heutling, D | 1 |
| Farhatullah, S | 1 |
| Keay, SD | 1 |
| Kennedy, CR | 1 |
| Harrison, C | 1 |
| Stepto, N | 1 |
| Hede, K | 1 |
| Venkatasubramanian, G | 1 |
| Elkind-Hirsch, K | 1 |
| Marrioneaux, O | 1 |
| Bhushan, M | 1 |
| Vernor, D | 1 |
| Bhushan, R | 1 |
| Dhakal-Karki, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)[NCT04029272] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-07-20 | Recruiting | ||
| Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study[NCT05702905] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| Obesity-related Mechanisms and Mortality in Breast Cancer Survivors[NCT01302379] | 333 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)[NCT02614859] | Phase 2 | 29 participants (Actual) | Interventional | 2015-12-01 | Completed | ||
| Effect of Metformin on Tibiofemoral Cartilage Volume and Knee Symptoms Among Overweighted Knee Osteoarthritis patients-a Randomized Clinical Trial[NCT05034029] | 262 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome[NCT04973891] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2021-04-07 | Completed | ||
| Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)[NCT01234649] | Phase 3 | 153 participants (Actual) | Interventional | 2011-08-11 | Completed | ||
| A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Der[NCT02106104] | Phase 4 | 48 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes[NCT02695810] | Phase 2 | 120 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities[NCT02338193] | Phase 3 | 69 participants (Actual) | Interventional | 2015-09-22 | Completed | ||
| Family Inclusive Childhood Obesity Treatment Designed for Low Income and Hispanic Families[NCT05041855] | 658 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | |||
| Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers[NCT03781102] | 120 participants (Anticipated) | Interventional | 2019-07-01 | Suspended (stopped due to COVID19) | |||
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)[NCT01952145] | Phase 3 | 557 participants (Actual) | Interventional | 2013-09-20 | Completed | ||
| Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial[NCT00375388] | Phase 3 | 400 participants | Interventional | 1998-01-31 | Completed | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder (ASD) While on Atypical Antipsychotic Medication[NCT03708614] | 10 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)[NCT01825798] | Phase 3 | 60 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus[NCT05556291] | 190 participants (Anticipated) | Observational | 2022-12-01 | Recruiting | |||
| A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects W[NCT02099110] | Phase 3 | 1,233 participants (Actual) | Interventional | 2014-04-22 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study[NCT02910817] | 102 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-15 | Recruiting | ||
| Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients[NCT01300637] | 60 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | |||
| Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation[NCT00930579] | Phase 2 | 35 participants (Actual) | Interventional | 2009-10-16 | Completed | ||
| A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin[NCT00734474] | Phase 2/Phase 3 | 1,202 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance[NCT00443755] | Phase 2 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Metformin in the Prevention of Alzheimer's Disease[NCT00620191] | Phase 2 | 80 participants (Actual) | Interventional | 2008-06-01 | Completed | ||
| A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficien[NCT01768559] | Phase 3 | 894 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment[NCT05298657] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-09-01 | Not yet recruiting | |||
| The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India[NCT01283308] | 599 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes[NCT01595789] | Phase 4 | 41 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes[NCT02730949] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort[NCT02910154] | 62 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429] | 35 participants (Actual) | Interventional | 2020-06-09 | Completed | |||
| WellStart Type 2 Diabetes Study[NCT03731533] | 0 participants (Actual) | Interventional | 2018-12-01 | Withdrawn (stopped due to Grantor withdrew from study) | |||
| Metabolic Syndrome and Severe Obesity: Randomized Nutritional Trial to Study Long Term Effect of Very-low-calories Ketogenic Diet (VLCKD) on Weight Control and Cardiovascular Risk Factors[NCT05781269] | 100 participants (Anticipated) | Interventional | 2022-02-20 | Recruiting | |||
| Benefits of Adding Continuous Glucose Monitoring to Glycemic Load, Exercise, and Monitoring of Blood Glucose (GEM) for Adults With Type 2 Diabetes - Phase 2[NCT03207893] | 24 participants (Actual) | Interventional | 2018-07-19 | Completed | |||
| Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification[NCT03196895] | 192 participants (Actual) | Interventional | 2017-06-28 | Completed | |||
| Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes[NCT03398902] | 150 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | |||
| Assessment of Designer Functional Foods on Parameters of Metabolic and Vascular Status in Individuals With Prediabetes.[NCT02400450] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn | |||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)[NCT00682890] | Phase 4 | 28 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Lack of recruitment) | ||
| A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone[NCT00039013] | Phase 3 | 336 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus[NCT00111540] | Phase 3 | 456 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb[NCT04625985] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-14 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison[NCT00451399] | Phase 4 | 128 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study[NCT01423487] | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn (stopped due to Difficult to obtain informed consent) | |||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome[NCT00344851] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bioavailable testosterone measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -13.7 |
| Placebo + Lifestyle Intervention | -4.5 |
| Metformin + Standard Dietary Guidelines | -11.1 |
| Placebo + Standard Dietary Guidelines | -1.3 |
C-reactive protein measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.4 |
| Placebo + Lifestyle Intervention | -6.7 |
| Metformin + Standard Dietary Guidelines | -9.2 |
| Placebo + Standard Dietary Guidelines | 5.9 |
Glucose measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -1.2 |
| Placebo + Lifestyle Intervention | -2.3 |
| Metformin + Standard Dietary Guidelines | -1.6 |
| Placebo + Standard Dietary Guidelines | 2.0 |
Insulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.8 |
| Placebo + Lifestyle Intervention | -17.7 |
| Metformin + Standard Dietary Guidelines | -13.2 |
| Placebo + Standard Dietary Guidelines | -1.1 |
Serum hormone binding globulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | 12.5 |
| Placebo + Lifestyle Intervention | 7.6 |
| Metformin + Standard Dietary Guidelines | 9.8 |
| Placebo + Standard Dietary Guidelines | -0.1 |
Participants with undetectable PSA after 32 weeks (NCT02614859)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 3 |
| Metformin and Bicalutamide | 5 |
Number of patients with BMI decline after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 4 |
| Arm B | 12 |
Median PSA decline after 8 weeks % (range) (NCT02614859)
Timeframe: 8 weeks
| Intervention | percent change (Median) |
|---|---|
| Bicalutamide | NA |
| Metformin and Bicalutamide | 9 |
Number of patients with PSA decline after 8 weeks (observation vs metformin) (NCT02614859)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 1 |
| Metformin and Bicalutamide | 8 |
Number of patients with PSA decline ≥ 85% after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 6 |
| Arm B | 10 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
Body weight in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | kilograms (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.2 |
| Metformin XR Plus Placebo | 91.3 |
Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 32.3 |
| Metformin XR Plus Placebo | 31 |
ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of ALT (U/L)/ AST (U/L) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 1.2 |
| Metformin XR Plus Placebo | 1.18 |
The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 27 |
| Metformin XR Plus Placebo | 28 |
BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | weight (kg) /height (m) squared (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 33.8 |
| Metformin XR Plus Placebo | 32.8 |
Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent. (NCT01234649)
Timeframe: Change from baseline (time 0) to study end (84 weeks)
| Intervention | percent change in weight from baseline (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | -7.2 |
| Metformin XR Plus Placebo | -3.1 |
DBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 77.6 |
| Metformin XR Plus Placebo | 77 |
Fasting glucose levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 90 |
| Metformin XR Plus Placebo | 91.7 |
HDL-C levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 51 |
| Metformin XR Plus Placebo | 48.7 |
HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.2 |
| Metformin XR Plus Placebo | 2.45 |
IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET) (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 418.4 |
| Metformin XR Plus Placebo | 333 |
IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 0.8 |
| Metformin XR Plus Placebo | 0.62 |
LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 110 |
| Metformin XR Plus Placebo | 107 |
OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 5.9 |
| Metformin XR Plus Placebo | 5.4 |
MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 121.6 |
| Metformin XR Plus Placebo | 118.8 |
SBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 122 |
| Metformin XR Plus Placebo | 123 |
CHOL levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 183.7 |
| Metformin XR Plus Placebo | 183.8 |
TRG concentrations in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 120 |
| Metformin XR Plus Placebo | 125 |
TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of TRG (mg/dL)/HDL-C (mg/dl) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.56 |
| Metformin XR Plus Placebo | 2.95 |
Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.3 |
| Metformin XR Plus Placebo | 95.3 |
Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist /height (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .56 |
| Metformin XR Plus Placebo | .57 |
Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist/hip circumference (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .81 |
| Metformin XR Plus Placebo | .81 |
BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | kg/m2 (Mean) |
|---|---|
| DAPA/MET XR | 33 |
| Dapaglifloxin | 33.7 |
| Metformin XR | 31 |
Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24 (NCT02338193)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | kilograms (Mean) |
|---|---|
| DAPA/MET XR | -21.5 |
| Dapaglifloxin | -12.5 |
| Metformin XR | -4.4 |
Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24 (NCT02338193)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percent weight loss from baseline (Mean) |
|---|---|
| DAPA/MET XR | -4.9 |
| Dapaglifloxin | -3.2 |
| Metformin XR | -1.1 |
Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment)
| Intervention | mmHG (Mean) |
|---|---|
| DAPA/MET XR | 79 |
| Dapaglifloxin | 77.8 |
| Metformin XR | 79 |
Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 89 |
| Dapaglifloxin | 91 |
| Metformin XR | 87 |
HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 2.6 |
| Dapaglifloxin | 2.4 |
| Metformin XR | 1.8 |
Corrected early insulin response to glucose challenge [(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)] with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 1.7 |
| Dapaglifloxin | 1.1 |
| Metformin XR | 0.77 |
ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| DAPA/MET XR | 1.13 |
| Dapaglifloxin | 1.12 |
| Metformin XR | 1.18 |
Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 6.0 |
| Dapaglifloxin | 6.3 |
| Metformin XR | 5.42 |
Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 109.5 |
| Dapaglifloxin | 110.1 |
| Metformin XR | 112.5 |
Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| DAPA/MET XR | 125 |
| Dapaglifloxin | 124 |
| Metformin XR | 119.6 |
Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 196 |
| Dapaglifloxin | 168 |
| Metformin XR | 178 |
Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 119 |
| Dapaglifloxin | 89.8 |
| Metformin XR | 212 |
Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| DAPA/MET XR | 95.6 |
| Dapaglifloxin | 95 |
| Metformin XR | 91.7 |
Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| DAPA/MET XR | 0.81 |
| Dapaglifloxin | 0.80 |
| Metformin XR | 0.83 |
Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| DAPA/MET XR | 0.58 |
| Dapaglifloxin | 0.57 |
| Metformin XR | 0.56 |
Change from baseline in body weight after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Kg (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.4 |
| Insulin Glargine (IGlar) | 1.8 |
Change from baseline in HbA1c after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Percentage (%) (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.81 |
| Insulin Glargine (IGlar) | -1.13 |
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia. (NCT01952145)
Timeframe: During 26 weeks of treatment
| Intervention | Number of episodes (Number) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | 289 |
| Insulin Glargine (IGlar) | 683 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI z-score (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.02 |
| Metformin | -0.08 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.45 |
| Metformin | -0.21 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI (kg/m2) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.52 |
| Metformin | -0.43 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (kg) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.80 |
| Metformin | 0.07 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.06 |
| Metformin | -0.63 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (z-score) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.04 |
| Metformin | -0.10 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in gluclose (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -2.41 |
| Metformin | -3.06 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in HDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.98 |
| Metformin | 3.27 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change insulin fasting (µIU/mL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.95 |
| Metformin | 1.97 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in LDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.41 |
| Metformin | -4.41 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change total cholesterol (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -3.29 |
| Metformin | -1.05 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in triglycerides (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 6.18 |
| Metformin | 5.74 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg | -1.02 |
| Ertugliflozin 15 mg | -1.08 |
| Sitagliptin 100 mg | -1.05 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | -1.49 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | -1.52 |
This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg | -2.69 |
| Ertugliflozin 15 mg | -3.74 |
| Sitagliptin 100 mg | -0.67 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | -2.52 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | -2.94 |
Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg | -35.73 |
| Ertugliflozin 15 mg | -36.91 |
| Sitagliptin 100 mg | -25.56 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | -43.96 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | -48.70 |
This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg | -3.89 |
| Ertugliflozin 15 mg | -3.69 |
| Sitagliptin 100 mg | -0.66 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | -3.42 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | -3.67 |
Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: 30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26
| Intervention | SBCSGI (10^-9min^-1) (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg | 8.62 |
| Ertugliflozin 15 mg | 9.71 |
| Sitagliptin 100 mg | 21.11 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | 16.24 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | 11.51 |
A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Week 26
| Intervention | Percentage of participants (Number) |
|---|---|
| Ertugliflozin 5 mg | 26.4 |
| Ertugliflozin 15 mg | 31.9 |
| Sitagliptin 100 mg | 32.8 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | 52.3 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | 49.2 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy. (NCT02099110)
Timeframe: Up to 52 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Ertugliflozin 5 mg | 3.2 |
| Ertugliflozin 15 mg | 3.2 |
| Sitagliptin 100 mg | 2.8 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | 3.3 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | 3.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy. (NCT02099110)
Timeframe: Up to 54 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Ertugliflozin 5 mg | 62.0 |
| Ertugliflozin 15 mg | 57.7 |
| Sitagliptin 100 mg | 57.5 |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | 58.8 |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | 55.7 |
This outcome measure examines the changes in tumor proliferation as measured by the amount of Ki-67 protein in the tumor. (NCT00930579)
Timeframe: Baseline, up to 4 weeks
| Intervention | percentage of ki-67 positive cells (Mean) | |
|---|---|---|
| Premetformin Tumor Sample | Post Metformin Tumor Sample | |
| Metformin | 2.17 | 2.165 |
The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| LY2189265 | 9 |
Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | kilograms (kg) (Mean) |
|---|---|
| 3.0 mg LY2189265 | -3.32 |
| 2.0 mg LY2189265 | -2.15 |
| 1.5 mg LY2189265 | -2.12 |
| 1.0 mg LY2189265 | -2.23 |
| 0.75 mg LY2189265 | -1.17 |
| 0.5 mg LY2189265 | -1.53 |
| 0.25 mg LY2189265 | -0.85 |
| Sitagliptin | -0.43 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.56 |
Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| 3.0 mg LY2189265 | -1.09 |
| 2.0 mg LY2189265 | -1.25 |
| 1.5 mg LY2189265 | -1.49 |
| 1.0 mg LY2189265 | -0.98 |
| 0.75 mg LY2189265 | -1.02 |
| 0.5 mg LY2189265 | -0.94 |
| 0.25 mg LY2189265 | -0.70 |
| Sitagliptin | -0.76 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.06 |
Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | beats per minute (bpm) (Mean) |
|---|---|
| 3.0 mg LY2189265 | 6.63 |
| 2.0 mg LY2189265 | 3.43 |
| 1.5 mg LY2189265 | 2.39 |
| 1.0 mg LY2189265 | 3.34 |
| 0.75 mg LY2189265 | -1.63 |
| 0.5 mg LY2189265 | 1.91 |
| 0.25 mg LY2189265 | 1.05 |
| Sitagliptin | -0.16 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.81 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT00734474)
Timeframe: Baseline, 52 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| 1.5 mg LY2189265 | -1.10 |
| 0.75 mg LY2189265 | -0.87 |
| Sitagliptin | -0.39 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| 3.0 mg LY2189265 | 0 |
| 2.0 mg LY2189265 | 0 |
| 1.5 mg LY2189265 | 0 |
| 1.0 mg LY2189265 | 0 |
| 0.75 mg LY2189265 | 0 |
| 0.5 mg LY2189265 | 0 |
| 0.25 mg LY2189265 | 0 |
| Sitagliptin | 2 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 |
| Placebo/Sitagliptin (26 Weeks Through 104 Weeks) | 1 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| 1.5 mg LY2189265 | 259 |
| 0.75 mg LY2189265 | 255 |
| Sitagliptin | 242 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 26 weeks
| Intervention | participants (Number) |
|---|---|
| 1.5 mg LY2189265 | 208 |
| 0.75 mg LY2189265 | 204 |
| Sitagliptin | 185 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 111 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | participants (Number) |
|---|---|
| 3.0 mg LY2189265 | 9 |
| 2.0 mg LY2189265 | 20 |
| 1.5 mg LY2189265 | 233 |
| 1.0 mg LY2189265 | 8 |
| 0.75 mg LY2189265 | 231 |
| 0.5 mg LY2189265 | 15 |
| 0.25 mg LY2189265 | 10 |
| Sitagliptin | 219 |
Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized. (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | nanograms times hours per milliliter (Mean) |
|---|---|
| 1.5 mg LY2189265 | 13378 |
| 0.75 mg LY2189265 | 7246 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | HOMA2-% (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| HOMA2-%B, 26 Weeks (n=206, 226, 206, 84) | HOMA2-%B, 52 Weeks (n=188, 198, 180) | HOMA2-%B, 104 Weeks (n=148, 154, 134) | HOMA2-%S, 26 Weeks (n=206, 226, 206, 84) | HOMA2-%S, 52 Weeks (n=188, 198, 180) | HOMA2-%S, 104 Weeks (n=148, 154, 134) | |
| 0.75 mg LY2189265 | 26.98 | 22.30 | 19.11 | 0.78 | 2.28 | -0.12 |
| 1.5 mg LY2189265 | 32.28 | 33.57 | 30.89 | 5.75 | 4.69 | 3.82 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.60 | NA | NA | 9.82 | NA | NA |
| Sitagliptin | 10.81 | 6.66 | 1.47 | 2.29 | 4.25 | 5.61 |
Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | kilograms (kg) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks | 52 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | -2.63 | -2.60 | -2.39 |
| 1.5 mg LY2189265 | -3.18 | -3.03 | -2.88 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -1.47 | NA | NA |
| Sitagliptin | -1.46 | -1.53 | -1.75 |
Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | millimeters of mercury (mmHg) (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sitting SBP, 26 Weeks (n=271, 278, 283, 138) | Sitting SBP, 104 Weeks (n=197, 192, 191) | Sitting DBP, 26 Weeks (n=271, 278, 283, 138) | Sitting DBP, 104 Weeks (n=197, 192, 191) | Standing SBP, 26 Weeks (n=271, 277, 281, 138) | Standing SBP, 104 Weeks (n=197, 192, 191) | Standing DBP, 26 Weeks (n=271, 277, 281, 138) | Standing DBP, 104 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | -1.40 | 1.28 | -0.20 | 1.40 | -1.72 | 0.17 | 0.03 | 0.36 |
| 1.5 mg LY2189265 | -1.73 | -0.07 | -0.43 | 0.38 | -1.53 | -1.30 | -0.11 | -0.23 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.12 | NA | 0.68 | NA | 0.26 | NA | -0.52 | NA |
| Sitagliptin | -1.94 | 0.02 | -1.06 | -0.36 | -2.54 | -1.20 | -1.36 | -0.67 |
Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | millimeters of mercury (mmHg) (Mean) | |
|---|---|---|
| Sitting SBP | Sitting DBP | |
| 0.25 mg LY2189265 | 1.67 | 1.28 |
| 0.5 mg LY2189265 | 0.40 | -0.75 |
| 0.75 mg LY2189265 | -6.21 | -3.18 |
| 1.0 mg LY2189265 | -2.00 | -0.08 |
| 1.5 mg LY2189265 | -4.77 | -1.20 |
| 2.0 mg LY2189265 | -4.63 | -1.17 |
| 3.0 mg LY2189265 | -8.85 | -1.21 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.61 | -0.22 |
| Sitagliptin | -2.16 | -1.11 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | milliseconds (msec) (Least Squares Mean) | |||
|---|---|---|---|---|
| PR Interval, 26 Weeks (n=256, 261, 268, 132) | PR Interval, 104 Weeks (n=168, 170, 167) | QTcF Interval, 26 Weeks (n=258, 262, 268, 132) | QTcF Interval, 104 Weeks (n=169, 170, 168) | |
| 0.75 mg LY2189265 | 1.60 | 3.06 | -2.44 | -2.49 |
| 1.5 mg LY2189265 | 2.94 | 4.59 | -3.86 | -2.71 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 2.24 | NA | 1.76 | NA |
| Sitagliptin | 0.42 | 3.19 | -1.31 | -0.02 |
Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | |||
|---|---|---|---|---|
| Sitting, 26 Weeks (n=271, 278, 283, 138) | Sitting, 104 Weeks (n=197, 192, 191) | Standing, 26 Weeks (n=271, 277, 281, 138) | Standing, 104 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | 1.90 | 2.77 | 2.00 | 2.50 |
| 1.5 mg LY2189265 | 2.57 | 2.28 | 3.24 | 2.26 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.22 | NA | -0.17 | NA |
| Sitagliptin | -0.11 | -0.78 | -0.24 | -1.06 |
Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 13, 26, 52, and 104 weeks
| Intervention | kilograms (kg) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=271, 278, 282, 138) | 52 Weeks Versus 26 Weeks (n=246, 255, 253) | 104 Weeks Versus 26 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | -0.57 | 0.06 | 0.32 |
| 1.5 mg LY2189265 | -0.53 | 0.17 | 0.42 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.37 | NA | NA |
| Sitagliptin | -0.42 | -0.04 | -0.39 |
Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 13, 26, 52, and 104 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=269, 269, 276, 136) | 52 Weeks Versus 26 Weeks (n=245, 254, 250) | 104 Weeks Versus 52 Weeks (n=194, 191, 190) | |
| 0.75 mg LY2189265 | 0.02 | 0.16 | 0.16 |
| 1.5 mg LY2189265 | -0.03 | 0.14 | 0.13 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.14 | NA | NA |
| Sitagliptin | 0.00 | 0.24 | 0.09 |
Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=265, 271, 276, 135) | 52 Weeks (n=239, 247, 244) | 104 Weeks (n=190, 187, 181) | |
| 0.75 mg LY2189265 | -1.97 | -1.63 | -1.39 |
| 1.5 mg LY2189265 | -2.38 | -2.38 | -1.99 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.49 | NA | NA |
| Sitagliptin | -0.97 | -0.90 | -0.47 |
Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | picomoles per liter (pmol/L) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=238, 249, 230, 115) | 52 Weeks (n=207, 218, 200) | 104 Weeks (n=187, 200, 183) | |
| 0.75 mg LY2189265 | 10.15 | 12.95 | 21.56 |
| 1.5 mg LY2189265 | 11.59 | 10.57 | 11.36 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -6.92 | NA | NA |
| Sitagliptin | 8.48 | 4.18 | 0.29 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) | |
|---|---|---|
| 26 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | -1.01 | -0.71 |
| 1.5 mg LY2189265 | -1.22 | -0.99 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0.03 | NA |
| Sitagliptin | -0.61 | -0.32 |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 Weeks | Severe HE, 104 Weeks | Documented Symptomatic HE, 26 Weeks | Documented Symptomatic HE, 104 Weeks | Asymptomatic HE, 26 Weeks | Asymptomatic HE, 104 Weeks | Nocturnal HE, 26 Weeks | Nocturnal HE, 104 Weeks | Probable HE, 26 Weeks | Probable HE, 104 Weeks | |
| 0.75 mg LY2189265 | 0 | 0 | 8 | 19 | 5 | 9 | 5 | 13 | 0 | 2 |
| 1.5 mg LY2189265 | 0 | 0 | 17 | 33 | 5 | 9 | 7 | 14 | 5 | 6 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 | NA | 2 | NA | 0 | NA | 0 | NA | 0 | NA |
| Sitagliptin | 0 | 0 | 10 | 18 | 0 | 3 | 2 | 10 | 2 | 6 |
Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Participants With Any CV Event | Participants With a Fatal CV Event | Participants With a Non-fatal CV Event | |
| 0.25 mg LY2189265 | 0 | 0 | 0 |
| 0.5 mg LY2189265 | 0 | 0 | 0 |
| 0.75 mg LY2189265 | 4 | 0 | 4 |
| 1.0 mg LY2189265 | 0 | 0 | 0 |
| 1.5 mg LY2189265 | 6 | 1 | 6 |
| 2.0 mg LY2189265 | 0 | 0 | 0 |
| 3.0 mg LY2189265 | 0 | 0 | 0 |
| Placebo/Sitagliptin (26 Weeks Through 104 Weeks) | 3 | 1 | 2 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 | 0 | 0 |
| Sitagliptin | 5 | 1 | 4 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR). (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphate, High (n=276, 258, 281) | ALT/SGPT, High (n=232, 237, 244) | Amylase Pancreatic, High (n=283, 277, 295) | Amylase Total, High (n=266, 265, 277) | AST/SGOT, High (n=273, 269, 284) | Basophils, High (n=276, 268, 288) | Basophils, Low (n=277, 268, 288) | Bilirubin Direct, High (n=295, 291, 307) | Bilirubin Total, High (n=295, 290, 305) | Calcitonin, High (n=233, 239, 235) | Chloride, High (n=299, 293, 310) | Chloride, Low (n=299, 293, 308) | CPK, High (n=273, 262, 276) | Creatinine, High (n=294, 285, 303) | Creatinine Clearance, High (n=164, 186, 180) | Creatinine Clearance, Low (n=292, 278, 303) | Eosinophils, High (n=265, 265, 284) | Eosinophils, Low (n=277, 268, 288) | Erythrocyte Count, High (n=283, 276, 292) | Erythrocyte Count, Low (n=278, 272, 285) | GGT, High (n=234, 240, 245) | Hematocrit, High (n=280, 274, 290) | Hematocrit, Low (n=262, 251, 269) | Hemoglobin, High (n=282, 275, 294) | Hemoglobin, Low (n=265, 253, 269) | Leukocyte Count, High (n=277, 270, 292) | Leukocyte Count, Low (n=277, 267, 284) | Lipase, High (n=255, 248, 269) | Lymphocytes, High (n=257, 262, 279) | Lymphocytes, Low (n=273, 266, 281) | MCHC, High (n=281, 274, 291) | MCHC, Low (n=280, 272, 290) | MCV, High (n=267, 256, 273) | MCV, Low (n=270, 261, 286) | Monocytes, High (n=274, 267, 284) | Monocytes, Low (n=271, 264, 283) | Neutrophils, High (n=272, 263, 286) | Neutrophils, Low (n=271, 260, 280) | Platelet Count, High (n=273, 268, 287) | Platelet Count, Low (n=270, 260, 275) | Potassium, High (n=297, 291, 307) | Potassium, Low (n=298, 293, 308) | Sodium, High (n=291, 291, 307) | Sodium, Low (n=298, 292, 305) | Urea Nitrogen, High (n=287, 282, 305) | UMCR, High (n=223, 212, 239) | |
| 0.75 mg LY2189265 | 11 | 37 | 78 | 55 | 27 | 0 | 0 | 1 | 8 | 3 | 2 | 2 | 41 | 16 | 32 | 25 | 22 | 0 | 2 | 14 | 24 | 6 | 24 | 3 | 28 | 9 | 7 | 132 | 20 | 9 | 0 | 4 | 25 | 3 | 1 | 14 | 12 | 6 | 3 | 7 | 9 | 8 | 10 | 1 | 29 | 27 |
| 1.5 mg LY2189265 | 13 | 29 | 81 | 44 | 21 | 1 | 0 | 2 | 3 | 5 | 0 | 3 | 52 | 11 | 26 | 24 | 12 | 0 | 3 | 18 | 16 | 3 | 30 | 4 | 30 | 13 | 9 | 142 | 19 | 5 | 0 | 5 | 39 | 9 | 3 | 10 | 15 | 10 | 2 | 8 | 14 | 8 | 10 | 5 | 17 | 38 |
| Sitagliptin | 20 | 39 | 61 | 43 | 36 | 1 | 0 | 3 | 6 | 4 | 1 | 3 | 54 | 9 | 34 | 20 | 14 | 0 | 1 | 19 | 45 | 3 | 29 | 2 | 25 | 8 | 14 | 126 | 21 | 12 | 0 | 5 | 25 | 4 | 11 | 17 | 13 | 10 | 3 | 8 | 8 | 5 | 6 | 5 | 29 | 30 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR). (NCT00734474)
Timeframe: Baseline through 26 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase (n=276, 258, 281, 162) | ALT/SGPT (n=232, 237, 244, 128) | Amylase Pancreatic, High (n=283, 277, 295, 160) | Amylase Total (n=266, 265, 277, 143) | AST/SGOT (n=273, 269, 284, 148) | Basophils, High (n=268, 259, 278, 163) | Basophils, Low (n=269, 259, 278, 163) | Bilirubin Direct, High (n=295, 291, 307, 171) | Bilirubin Total, High (n=295, 290, 305, 168) | Calcitonin, High (n=226, 233, 230, 113) | Chloride, High (n=299, 293, 310, 174) | Chloride, Low (n=299, 293, 308, 174) | CPK, High (n=273, 262, 276, 156 | Creatinine, High (n=294, 285, 303, 172) | Creatinine Clearance, High (n=164, 186, 180, 107) | Creatinine Clearance, Low (n=292, 278,303,168) | Eosinophils, High (n=258, 256, 275, 157) | Eosinophils, Low (n=269, 259, 278, 163) | Erythrocyte Count, High (n=279, 272, 287, 164) | Erythrocyte Count, Low (n=274, 268, 280, 161) | GGT, High (n=234, 240, 245, 144) | Hematocrit, High (n=273, 265, 279, 161) | Hematocrit, Low (n=256, 242, 259, 157) | Hemoglobin, High (n=278, 271, 289, 164) | Hemoglobin, Low (n=262, 249, 265, 162) | Leukocyte Count, High (n=272, 265, 286, 165) | Leukocyte Count, Low (n=272, 262, 280, 165) | Lipase, High (n=255, 248, 269, 147) | Lymphocytes, High (n=249, 253, 269, 161) | Lymphocytes, Low (n=265, 258, 273, 159) | MCHC, High (n=274, 265, 280, 163) | MCHC, Low (n=273, 263, 279, 163) | MCV, High (n=261, 248, 263, 156) | MCV, Low (n=264, 252, 275, 162) | Monocytes, High (n=266, 258, 274, 163) | Monocytes, Low (n=265, 255, 274, 158) | Neutrophils, High (n=264, 255, 276, 161) | Neutrophils, Low (n=263, 251, 271, 162) | Platelet Count, High (n=265, 260, 281, 160) | Platelet Count, Low (n=262, 252, 269, 154) | Potassium, High (n=297, 291, 307, 172) | Potassium, Low (n=298, 293, 308, 169) | Sodium, High (n=291, 291, 307, 170) | Sodium, Low (n=298, 292, 305, 174) | Urea Nitrogen, High (n=287, 282, 305, 169) | UMCR, High (n=217, 204, 232, 130) | |
| 0.75 mg LY2189265 | 3 | 24 | 55 | 33 | 12 | 0 | 0 | 1 | 4 | 2 | 1 | 2 | 20 | 10 | 28 | 17 | 11 | 0 | 1 | 7 | 11 | 1 | 10 | 1 | 16 | 6 | 3 | 92 | 9 | 3 | 0 | 2 | 12 | 2 | 0 | 5 | 5 | 1 | 0 | 3 | 2 | 6 | 4 | 1 | 17 | 9 |
| 1.5 mg LY2189265 | 9 | 18 | 54 | 33 | 14 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 29 | 7 | 17 | 11 | 4 | 0 | 1 | 12 | 9 | 1 | 13 | 1 | 13 | 3 | 2 | 109 | 5 | 3 | 0 | 0 | 19 | 3 | 1 | 6 | 4 | 2 | 0 | 2 | 7 | 4 | 3 | 2 | 11 | 18 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 3 | 8 | 18 | 13 | 7 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 7 | 5 | 25 | 6 | 2 | 0 | 0 | 3 | 10 | 2 | 5 | 2 | 3 | 0 | 1 | 37 | 3 | 2 | 0 | 0 | 5 | 0 | 1 | 10 | 1 | 1 | 0 | 3 | 4 | 1 | 4 | 1 | 5 | 5 |
| Sitagliptin | 12 | 25 | 42 | 27 | 18 | 1 | 0 | 1 | 4 | 2 | 0 | 1 | 30 | 5 | 26 | 12 | 6 | 0 | 0 | 7 | 23 | 1 | 6 | 1 | 5 | 1 | 4 | 97 | 6 | 4 | 0 | 0 | 14 | 2 | 3 | 8 | 3 | 2 | 1 | 6 | 5 | 3 | 4 | 4 | 13 | 13 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) . (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase, High (n=276, 258, 281) | ALT/SGPT, High (n=232, 237, 244) | Amylase Pancreatic, High (n=283, 277, 295) | Amylase Total, High (n=266, 265, 277) | AST/SGOT, High (n=273, 269, 284) | Basophils, High (n=276, 268, 287) | Basophils, Low (n=277, 268, 287) | Bilirubin Direct, High (n=295, 291, 307) | Bilirubin Total, High (n=295, 290, 305) | Calcitonin, High (n=233, 239, 235) | Chloride, High (n=299, 293, 310) | Chloride, Low (n=299, 293, 308) | CPK, High (n=273, 262, 276) | Creatinine, High (n=294, 285, 303) | Creatinine Clearance, High (n=164, 186, 180) | Creatinine Clearance, Low (n=292, 278, 303) | Eosinophils, High (n=265, 265, 283) | Eosinophils, Low (n=277, 268, 287) | Erythrocyte Count, High (n=283, 276, 292) | Erythrocyte Count, Low (n=278, 272, 285) | GGT, High (n=234, 240, 245) | Hematocrit, High (n=280, 274, 290) | Hematocrit, Low (n=262, 251, 269) | Hemoglobin, High (n=282, 275, 294) | Hemoglobin, Low (n=265, 253, 269) | Leukocyte Count, High (n=277, 270, 292) | Leukocyte Count, Low (n=277, 267, 284) | Lipase, High (n=255, 248, 269) | Lymphocytes, High (n=257, 262, 278) | Lymphocytes, Low (n=273, 266, 280) | MCHC, High (n=281, 274, 291) | MCHC, Low (n=280, 272, 290) | MCV, High (n=267, 256, 273) | MCV, Low (n=270, 261, 286) | Monocytes, High (n=274, 267, 283) | Monocytes, Low (n=271, 264, 282) | Neutrophils, High (n=272, 263, 285) | Neutrophils, Low (n=271, 260, 279) | Platelet Count, High (n=272, 267, 287) | Platelet Count, Low (n=269, 259, 275) | Potassium, High (n=297, 291, 307) | Potassium, Low (n=298, 293, 308) | Sodium, High (n=291, 291, 307) | Sodium, Low (n=298, 292, 305) | Urea Nitrogen, High (n=287, 282, 305) | UMCR, High (n=223, 212, 238) | |
| 0.75 mg LY2189265 | 6 | 27 | 70 | 42 | 19 | 0 | 0 | 1 | 6 | 2 | 1 | 2 | 28 | 10 | 30 | 20 | 14 | 0 | 1 | 9 | 14 | 2 | 13 | 1 | 19 | 6 | 3 | 111 | 15 | 4 | 0 | 3 | 18 | 2 | 0 | 9 | 7 | 2 | 2 | 5 | 5 | 7 | 8 | 1 | 19 | 21 |
| 1.5 mg LY2189265 | 10 | 25 | 67 | 38 | 15 | 1 | 0 | 1 | 2 | 4 | 0 | 1 | 38 | 9 | 23 | 18 | 11 | 0 | 3 | 15 | 10 | 3 | 21 | 3 | 21 | 7 | 5 | 124 | 12 | 4 | 0 | 2 | 25 | 3 | 1 | 8 | 8 | 6 | 0 | 4 | 10 | 6 | 5 | 3 | 14 | 33 |
| Sitagliptin | 16 | 28 | 55 | 36 | 25 | 1 | 0 | 2 | 5 | 2 | 0 | 2 | 43 | 6 | 29 | 15 | 10 | 0 | 1 | 11 | 34 | 2 | 11 | 1 | 11 | 3 | 9 | 110 | 11 | 11 | 0 | 3 | 19 | 4 | 5 | 15 | 7 | 6 | 2 | 8 | 5 | 5 | 4 | 4 | 21 | 18 |
The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, High, 26 Weeks (n=144, 158, 139, 58) | Cholesterol, High, 104 Weeks (n=151, 164, 146) | HDL-C, High, 26 Weeks (n=197, 201, 189, 78) | HDL-C, Low, 26 Weeks (n=127, 137, 129, 52) | HDL-C, High, 104 Weeks (n=206, 212, 199) | HDL-C, Low, 104 Weeks (n=134, 143, 138) | LDL-C, High, 26 Weeks (n=155, 163, 150, 61) | LDL-C, High, 104 Weeks (n=163, 170, 157) | TG, High, 26 Weeks (n=163, 174, 156, 64) | TG, High, 104 Weeks (n=170, 183, 166) | |
| 0.75 mg LY2189265 | 21 | 29 | 0 | 13 | 1 | 20 | 11 | 23 | 13 | 22 |
| 1.5 mg LY2189265 | 16 | 34 | 1 | 9 | 2 | 13 | 15 | 31 | 6 | 13 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 8 | NA | 0 | 1 | NA | NA | 7 | NA | 2 | NA |
| Sitagliptin | 20 | 34 | 0 | 8 | 2 | 13 | 19 | 29 | 10 | 15 |
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00734474)
Timeframe: Baseline, 52 weeks, and 104 weeks
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| EQ-5D, UK, Baseline (n=285, 281, 300) | EQ-5D, UK, 52 Weeks (n=237, 250, 244) | EQ-5D, UK, 104 Weeks (n=189, 190, 185) | VAS, Baseline (n=285, 284, 301) | VAS, 52 Weeks (n=238, 251, 245) | VAS, 104 Weeks (n=189, 190, 185) | |
| 0.75 mg LY2189265 | 0.82 | 0.84 | 0.86 | 75.35 | 78.22 | 78.52 |
| 1.5 mg LY2189265 | 0.80 | 0.83 | 0.84 | 75.57 | 78.93 | 79.66 |
| Sitagliptin | 0.84 | 0.85 | 0.86 | 76.85 | 78.79 | 81.34 |
"The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = always true and 1 = never true. Items are summed into 6 scales (physical function [11 items], self-esteem [7 items], sexual life [4 items], public distress [5 items], work [4 items], and total score [31 items]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale." (NCT00734474)
Timeframe: Baseline, 52 weeks, and 104 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Total Score, Baseline (n=285, 284, 300) | Total Score, 52 Weeks (n=237, 252, 247) | Total Score, 104 Weeks (n=190, 190, 185) | |
| 0.75 mg LY2189265 | 82.55 | 86.31 | 87.47 |
| 1.5 mg LY2189265 | 83.41 | 86.92 | 88.08 |
| Sitagliptin | 83.97 | 86.25 | 86.93 |
The percentage of participants achieving HbA1c levels <7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| <7.0% at 26 Weeks | <7.0% at 52 Weeks | <7.0% at 104 Weeks | ≤6.5% at 26 Weeks | ≤6.5% at 52 Weeks | ≤6.5% at 104 Weeks | |
| 0.75 mg LY2189265 | 55.2 | 48.8 | 44.8 | 31.0 | 29.0 | 24.2 |
| 1.5 mg LY2189265 | 60.9 | 57.6 | 54.3 | 46.7 | 41.7 | 39.1 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 21.0 | NA | NA | 12.5 | NA | NA |
| Sitagliptin | 37.8 | 33.0 | 31.1 | 21.8 | 19.2 | 14.1 |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | episodes per participant per year (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 Weeks | Severe HE, 104 Weeks | Documented Symptomatic HE, 26 Weeks | Documented Symptomatic HE, 104 Weeks | Asymptomatic HE, 26 Weeks | Asymptomatic HE, 104 Weeks | Nocturnal HE, 26 Weeks | Nocturnal HE, 104 Weeks | Probable Symptomatic HE, 26 Weeks | Probable Symptomatic HE, 104 Weeks | |
| 0.75 mg LY2189265 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| 1.5 mg LY2189265 | 0.0 | 0.0 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0.0 | NA | 0.1 | NA | 0.0 | NA | 0.0 | NA | 0.0 | NA |
| Sitagliptin | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
The number of visits to the emergency room (ER) is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 52 and 104 weeks
| Intervention | events (Number) | |
|---|---|---|
| 52 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | NA | NA |
| 1.5 mg LY2189265 | NA | NA |
| Sitagliptin | NA | NA |
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | centimeters (cm) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=266, 273, 277, 138) | 52 Weeks (n=238, 250, 247) | 104 Weeks (n=192, 189, 188) | |
| 0.75 mg LY2189265 | -1.78 | -2.05 | -1.75 |
| 1.5 mg LY2189265 | -2.89 | -2.91 | -2.57 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -1.20 | NA | NA |
| Sitagliptin | -1.45 | -1.45 | -1.20 |
Body fat is reported as a percentage of body weight. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage of body weight (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 1.73 |
| Placebo | -0.01 |
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 0.37 |
| Placebo | -0.21 |
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -19.96 |
| Placebo | 8.39 |
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -1.13 |
| Placebo | -0.34 |
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.35 |
| Placebo | 0.19 |
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL). (NCT00443755)
Timeframe: Baseline, 3 month
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.13 |
| Placebo | 0.18 |
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | microIU/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -8.13 |
| Placebo | 1.38 |
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | micromols/kg of FFM/minute (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 17.95 |
| Placebo | 1.68 |
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 9.10 |
| Placebo | 0.46 |
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.19 |
| Placebo | -0.15 |
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.99 |
| Placebo | -1.42 |
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 14.00 |
| Placebo | -18.62 |
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -34.17 |
| Placebo | 8.15 |
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Triglycerides | HDL-C-Cholesterol | Non-HDL-Cholesterol | |
| Insulin Sensitizer Therapy | -15.58 | 4.33 | -7.50 |
| Placebo | 17.77 | -0.31 | 4.62 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
Change in plasma Amyloid beta-42 from baseline to 12 months (NCT00620191)
Timeframe: 12 months
| Intervention | pg/ml (Mean) |
|---|---|
| Placebo | -4.40 |
| Metformin | 0.69 |
Change in relative glucose uptake (rCMRgl) in the posterior cingulate-precuneus measured with subscale (ADAS-Cog) from brain [18]F-labeled 2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET). The unit for rCMRgl is %. The results presented are absolute differences in rCMRgl, presented in % units; the change was calculated subtracting the baseline rCMRgl from the follow-up rCMRgl (NCT00620191)
Timeframe: 12 months
| Intervention | percentage of rCMRgl (Mean) |
|---|---|
| Placebo | 0.0 |
| Metformin | 2.0 |
The ADAS-cog is an aggregate for several cognitive tests intended to provide a global cognitive score and consists of 11 tasks. The tasks (and corresponding score range)) are Word Recall (0-10), Naming (0-4), Commands (0-5), Constructional Praxis (0-5) Ideational Praxis (0-5), Orientation (0-8), Word Recognition (0-12), Language (0-5), Word Finding Difficulty (0-5), and Remembering Test Instructions (1-5). The range of aggregate scores (sum of scores) is 1 to 69, with higher scores meaning worse cognitive performance. The change was calculated subtracting the baseline score from the final visit score. (NCT00620191)
Timeframe: 12 months
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.98 |
| Metformin | 0.0 |
The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance. The total recall score from the first visit was subtracted from that of the last visit to calculate the change in score (total words recalled). (NCT00620191)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 5.7 |
| Metformin | 9.4 |
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime three times in a week before baseline, before visit Week 12 and before visit week 26 and the average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lixisenatide | -0.784 |
| Insulin Glulisine QD | -0.782 |
| Insulin Glulisine TID | -1.053 |
"Primary outcome was the comparison between Lixisenatide versus Insulin Glulisine TID.~Change in body weight was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug." (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lixisenatide | -0.63 |
| Insulin Glulisine QD | 1.03 |
| Insulin Glulisine TID | 1.37 |
Change in FPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lixisenatide | -0.23 |
| Insulin Glulisine QD | -0.21 |
| Insulin Glulisine TID | -0.06 |
Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change in glucose excursions was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Lixisenatide | -3.42 |
| Insulin Glulisine QD | -1.59 |
| Insulin Glulisine TID | -1.56 |
Change in HbA1C was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using last on-treatment observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | percentage of hemoglobin (Least Squares Mean) |
|---|---|
| Lixisenatide | -0.63 |
| Insulin Glulisine QD | -0.58 |
| Insulin Glulisine TID | -0.84 |
Change in Insulin glargine dose was calculated by subtracting the baseline value from Week 26 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | U (Least Squares Mean) |
|---|---|
| Lixisenatide | 0.7 |
| Insulin Glulisine QD | -0.06 |
| Insulin Glulisine TID | -3.13 |
The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change in PPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug. (NCT01768559)
Timeframe: Baseline, Week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Lixisenatide | -3.93 |
| Insulin Glulisine QD | -1.62 |
| Insulin Glulisine TID | -1.87 |
The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug. Missing data was imputed using LOCF. (NCT01768559)
Timeframe: Week 26
| Intervention | U (Mean) |
|---|---|
| Insulin Glulisine QD | 9.97 |
| Insulin Glulisine TID | 20.24 |
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for body weight assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. (NCT01768559)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Lixisenatide | 31.2 |
| Insulin Glulisine QD | 16.7 |
| Insulin Glulisine TID | 17.6 |
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for symptomatic hypoglycemia assessment was defined as the time from the first dose of study drug up to 1 day after the last dose of study drug. (NCT01768559)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Lixisenatide | 29.4 |
| Insulin Glulisine QD | 24.2 |
| Insulin Glulisine TID | 26.1 |
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for body weight assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. The on-treatment period for symptomatic hypoglycemia assessment was defined as the time from the first dose of study drug up to 1 day after the last dose of study drug. Participants without post-baseline on-treatment values (HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (HbA1c and/or body weight) was available and showed non-response, or if they experienced at least one documented symptomatic hypoglycemia during the on-treatment period. Otherwise, they were counted as missing data. (NCT01768559)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Lixisenatide | 22.2 |
| Insulin Glulisine QD | 9.2 |
| Insulin Glulisine TID | 10.8 |
The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 3 days after the last dose of study drug. (NCT01768559)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Lixisenatide | 64.7 |
| Insulin Glulisine QD | 36.6 |
| Insulin Glulisine TID | 30.5 |
"The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug. Missing data was imputed using LOCF.~The outcome is reporting results of total insulin (amounts of Insulin Glargine plus Insulin Glulisine ) only for the arms in which Insulin Glulisine was administered and is not applicable for the lixisenatide arm in which only Insulin Glargine is administered. Change in dose of the insulin used by patients in the Lixisenatide arm (i.e. Insulin Glargine) is reported in the secondary Outcome Measure 9." (NCT01768559)
Timeframe: Week 26
| Intervention | U (Mean) |
|---|---|
| Insulin Glulisine QD | 73.61 |
| Insulin Glulisine TID | 81.05 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of <60 mg/dL (3.3 mmol/L). Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the participant required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. (NCT01768559)
Timeframe: First dose of study drug up to 3 days after the last dose administration (maximum of 185 days)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Documented symptomatic hypoglycemia | Severe symptomatic hypoglycemia | |
| Insulin Glulisine QD | 37.5 | 0.7 |
| Insulin Glulisine TID | 44.6 | 0 |
| Lixisenatide | 31.5 | 0 |
The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Missing data was imputed using LOCF. (NCT01768559)
Timeframe: Week 26
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HbA1c ≤6.5% | HbA1c <7.0% | |
| Insulin Glulisine QD | 17.8 | 38.4 |
| Insulin Glulisine TID | 30.8 | 49.2 |
| Lixisenatide | 20.5 | 42.1 |
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | min-1/(µlU/L) (Mean) | ||
|---|---|---|---|
| SI at baseline | SI at 3 months | SI change vs baseline | |
| Metformin | 3.83 | 2.11 | -1.72 |
| Placebo | 2.26 | 2.8 | 0.544 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| ISI at baseline | ISI at month 3 | ISI change vs baseline | |
| Metformin | 7.3 | 5.9 | -1.4 |
| Placebo | 4.7 | 4.4 | -0.3 |
32 reviews available for metformin and Overweight
| Article | Year |
|---|---|
Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials.
Topics: Breast Neoplasms; Cancer Survivors; Female; Humans; Metabolomics; Metformin; Obesity; Overweight; Ph | 2022 |
Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Hormones; Humans; H | 2020 |
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; | 2020 |
Pharmacotherapeutic options for prediabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2021 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycem | 2021 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; | 2018 |
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age | 2017 |
Prevention of Excessive Gestational Weight Gain and Postpartum Weight Retention.
Topics: Adult; Anti-Obesity Agents; Diet, Healthy; Diet, Reducing; Evidence-Based Medicine; Exercise; Female | 2018 |
The effects of metformin on simple obesity: a meta-analysis.
Topics: Body Mass Index; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Treatment Outcome | 2018 |
Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.
Topics: Adult; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2018 |
Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Obesity; Overweigh | 2019 |
Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Overwei | 2019 |
The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis.
Topics: Contraceptives, Oral, Hormonal; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Life Style; Met | 2019 |
[Diabetes drugs and body weight].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Prognosis; R | 2013 |
Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.
Topics: Body Mass Index; Caloric Restriction; Evidence-Based Medicine; Exercise; Female; Humans; Hypoglycemi | 2013 |
Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Melli | 2014 |
Prevention of gestational diabetes mellitus: Where are we now?
Topics: Diabetes, Gestational; Diet; Dietary Supplements; Exercise Therapy; Female; Humans; Hypoglycemic Age | 2015 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction.
Topics: Adult; Anovulation; Body Weight; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans | 2016 |
The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Drug Monitoring; Drug Therapy, Combination; Evi | 2017 |
The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Humans; Hypoglycemic Agents; Metformin; Obesity; O | 2010 |
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hyp | 2011 |
Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agen | 2012 |
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metformin; Outcome Assessment, Health Care | 2012 |
The clinical treatment of childhood obesity.
Topics: Adolescent; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; | 2013 |
Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hypoglycemic Agents; Life Style; M | 2012 |
Is metformin the treatment of choice for anovulation in polycystic ovary syndrome?
Topics: Anovulation; Female; Humans; Metformin; Overweight; Polycystic Ovary Syndrome; Risk Reduction Behavi | 2007 |
Pharmacotherapeutic options for overweight adolescents.
Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents | 2007 |
Role of metformin for weight management in patients without type 2 diabetes.
Topics: Adolescent; Adult; Anti-Obesity Agents; Body Weight; Clinical Trials as Topic; Humans; Hypoglycemic | 2008 |
93 trials available for metformin and Overweight
| Article | Year |
|---|---|
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
[Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Orlist | 2021 |
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
Topics: Adult; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2022 |
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed C | 2022 |
Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? Study protocol for a randomized, double-blind, and placebo-controlled trial.
Topics: Cartilage; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Metformin; Multicenter Studies as | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; O | 2022 |
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
Topics: Female; Follicle Stimulating Hormone; Glucose; Humans; Liraglutide; Metabolome; Metformin; Obesity; | 2022 |
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind M | 2022 |
Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity.
Topics: Child; Diet; Female; Follow-Up Studies; Humans; Life Style; Metformin; Overweight; Pediatric Obesity | 2023 |
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Female; Humans; Insulin; Insulin Resistance; Metabo | 2022 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; | 2023 |
Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes.
Topics: Adolescent; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemi | 2023 |
Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
Topics: Adult; Blood Glucose; Body Weight; Cardiometabolic Risk Factors; Cholesterol; Diabetes Mellitus, Typ | 2023 |
Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2020 |
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Energy Met | 2020 |
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Topics: Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptida | 2020 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intol | 2021 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Gl | 2021 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; | 2020 |
Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial.
Topics: Body Composition; Diabetes Mellitus, Type 2; Humans; Insulin; Metformin; Overweight | 2021 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; D | 2018 |
Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Diabetes | 2018 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fem | 2017 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidy | 2018 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidy | 2018 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidy | 2018 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidy | 2018 |
Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial.
Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Die | 2017 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility | 2019 |
Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Topics: Adipose Tissue; Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Combinations; Ethi | 2018 |
Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Double-Blind Method; Female; Huma | 2018 |
Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post-hoc analysis of a randomized placebo-controlled trial.
Topics: 25-Hydroxyvitamin D 2; Age Factors; Aged; Body Mass Index; Calcifediol; Diabetes Mellitus, Type 2; D | 2018 |
Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hy | 2019 |
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
Topics: Adult; Diet Therapy; Double-Blind Method; Exercise; Female; Fetal Macrosomia; Gestational Weight Gai | 2019 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2019 |
Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
Topics: Adipokines; Adult; Biomarkers; Blood Glucose; Carrier Proteins; Exenatide; Female; Glycoproteins; Hu | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Sex hormone binding globulin and sex steroids among premenopausal women in the diabetes prevention program.
Topics: Adult; Black or African American; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus; Die | 2013 |
Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Topics: Adult; Body Weight; Clozapine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Metabol | 2013 |
Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Female; Follow-Up Studies; Gonadal Steroid Hormones; Hu | 2014 |
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cell Proliferatio | 2014 |
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2014 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidas | 2014 |
Weight loss increases follicle stimulating hormone in overweight postmenopausal women [corrected].
Topics: Aged; Behavior Therapy; Body Weight; Diabetes Mellitus, Type 2; Estradiol; Female; Follicle Stimulat | 2015 |
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
Topics: Adrenal Cortex; Adult; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Hype | 2014 |
Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial.
Topics: Adolescent; Blood Pressure; Body Composition; Body Mass Index; Child; Combined Modality Therapy; Die | 2014 |
Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Cross-Sectional Studies; Female; Fibronectins; Glucose Tolerance Test; Humans; Hypoglycemic A | 2015 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose C | 2015 |
Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellit | 2015 |
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; D | 2015 |
Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Topics: Amylases; Blood Glucose; Body Fat Distribution; Body Weight; Diabetes Mellitus, Type 2; Drug Adminis | 2015 |
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Topics: Adult; Body Mass Index; Cross-Sectional Studies; Female; Gonadal Steroid Hormones; Humans; Hypoglyce | 2016 |
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
Topics: Aged; Aged, 80 and over; Blood Glucose; Breast Neoplasms; C-Reactive Protein; Estradiol; Exercise; F | 2016 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program.
Topics: Adult; Betaine; Biomarkers; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Diabete | 2016 |
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Brain; Cognitive Dysfunction; Double-Blind Method; F | 2016 |
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Bli | 2016 |
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Topics: Adiponectin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Combined Modalit | 2016 |
Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
Topics: Acarbose; Adult; Aged; Asian People; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type | 2017 |
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2016 |
Testosterone and depressive symptoms among men in the Diabetes Prevention Program.
Topics: Adult; Depression; Diabetes Mellitus; Follow-Up Studies; Glucose Metabolism Disorders; Humans; Hypog | 2016 |
The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diet; Female; Follow-Up Studies; Glucose I | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Topics: Aged; Circadian Rhythm; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Doub | 2017 |
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Folic Acid; Humans; Inositol; I | 2017 |
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Topics: Behavior Therapy; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Fe | 2008 |
The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glycated H | 2009 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.
Topics: Adiponectin; Adiposity; Aldosterone; Biomarkers; Body Mass Index; Cross-Sectional Studies; Female; H | 2010 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
The effect of comprehensive lifestyle intervention or metformin on obesity in young women.
Topics: Adolescent; Adult; Behavior Therapy; Body Composition; Body Mass Index; Body Weight; Double-Blind Me | 2011 |
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
Topics: Adult; Alanine Transaminase; Biomarkers; Diabetes Mellitus; Fatty Liver; Female; Glucose Intolerance | 2010 |
Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS.
Topics: Adrenocorticotropic Hormone; Adult; Dehydroepiandrosterone Sulfate; Drug Synergism; Drug Therapy, Co | 2010 |
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Ora | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2012 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 2013 |
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Ins | 2013 |
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glycated | 2006 |
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Cardiovascular Physiological Phenomena; Contraceptives, Or | 2007 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2008 |
Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Contraceptives, Oral; Cyproterone; Ethinyl Estradiol; Female; Glucose Tolera | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
73 other studies available for metformin and Overweight
| Article | Year |
|---|---|
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metfor | 2022 |
An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.
Topics: Aged; Aging; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Overweight | 2021 |
Screening for Prediabetes and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetes, Gestational; Exercise; Female; Humans; Hypoglycemi | 2022 |
Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity.
Topics: Adolescent; Adult; Child; Humans; Metformin; Models, Biological; Obesity, Morbid; Overweight; Pediat | 2022 |
Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus.
Topics: Cesarean Section; Diabetes, Gestational; Female; Glucose; Humans; Insulin, Short-Acting; Metformin; | 2022 |
Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Humans; Lipid Droplets; Lipids; Metformin; Obesit | 2022 |
Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Humans; Inpatients; Insulin Resistance; Metfor | 2022 |
Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation.
Topics: Adult; Body Mass Index; Female; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; O | 2022 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries.
Topics: Humans; Mammary Arteries; Metformin; Monoamine Oxidase; Overweight; Oxidative Stress; Reactive Oxyge | 2023 |
The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank.
Topics: Back Pain; Biological Specimen Banks; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, T | 2023 |
Beneficial effects of metformin on mice female fertility after a high-fat diet intake.
Topics: Animals; Diet, High-Fat; Female; Fertility; Infertility; Metformin; Mice; Mice, Inbred C57BL; Overwe | 2023 |
Management of Type 2 Diabetes in Frail Older Adults.
Topics: Aged; Diabetes Mellitus, Type 2; Frail Elderly; Frailty; Humans; Hypoglycemic Agents; Metformin; Obe | 2023 |
Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Gestational Weight Gain; Humans; Hypoglycemic A | 2019 |
Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Topics: Adult; Area Under Curve; Birth Weight; Cell Hypoxia; Delivery, Obstetric; Diabetes, Gestational; Ele | 2021 |
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes.
Topics: Adult; Combined Modality Therapy; Exercise; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metf | 2017 |
Antipsychotic-Induced Weight Gain and Metformin.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2017 |
Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Anti-Obesity Agents; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethin | 2018 |
PCOS: Metformin risk for offspring.
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Letter to the Editor: "Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs".
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Response to Letter to the Editor: "Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs".
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Mobility for All?
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Double-Blind Method; Humans; Metf | 2018 |
Dr. Handen et al. Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Humans; Metformin; Overweight; We | 2018 |
Drs. Walkup and Cottingham Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2018 |
Reassessing strategies to improve pregnancy outcomes in overweight and obese women.
Topics: Double-Blind Method; Female; Humans; Life Style; Metformin; Obesity; Overweight; Pregnancy; Pregnanc | 2019 |
Abdominal Fat SIRT6 Expression and Its Relationship with Inflammatory and Metabolic Pathways in Pre-Diabetic Overweight Patients.
Topics: Abdominal Fat; Adult; Down-Regulation; Female; Humans; Male; Metformin; Middle Aged; NF-kappa B; Ove | 2019 |
Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Contraceptive Devices, Female; Female; Glucose To | 2019 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |
Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome.
Topics: Adipokines; Adult; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Carotid | 2013 |
Metformin inhibits skin tumor promotion in overweight and obese mice.
Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet; | 2014 |
Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study.
Topics: Blood Glucose; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycated Hem | 2013 |
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Topics: Adolescent; Austria; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Ang | 2015 |
How does obesity affect fertility in men - and what are the treatment options?
Topics: Adiposity; Androgens; Aromatase Inhibitors; Body Mass Index; Clomiphene; Erectile Dysfunction; Estro | 2015 |
The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study.
Topics: Adult; Biopsy; Body Mass Index; Cohort Studies; Cyclin D2; Endometrial Neoplasms; Endometrium; Femal | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Total Antioxidant Status in Type 2 Diabetic Patients in Palestine.
Topics: Antioxidants; Arabs; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Educational Status; | 2015 |
[Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance].
Topics: Chile; Delphi Technique; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metfor | 2015 |
IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Humans; Hypogl | 2015 |
A Sensitivity Analysis to Assess Bias Due to Selecting Subjects Based on Treatment Received.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combin | 2016 |
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Topics: Adenocarcinoma; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Body | 2016 |
[Treatment of type 2 diabetes with metformin].
Topics: Administration, Oral; Body Mass Index; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglyce | 2015 |
Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Topics: Acarbose; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hum | 2016 |
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Huma | 2016 |
Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Glucose Tolerance Test; Humans; Insulin Antagonists; | 2017 |
Diagnosis and Treatment of Polycystic Ovary Syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Hypogl | 2016 |
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
Topics: Active Transport, Cell Nucleus; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2017 |
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Topics: Body Mass Index; Body Size; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Greece; | 2009 |
Treatment of white coat hypertension with metformin.
Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human | 2008 |
A summary of the ADVANCE Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progr | 2009 |
Continuation of metformin after introduction of insulin in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformi | 2009 |
Metformin provides weight reduction for hospitalized patients receiving polypharmacy.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Male; Metformin; Middle Aged; Overweig | 2010 |
Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular Diseases; Diet; | 2010 |
Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism.
Topics: Female; Humans; Hypoglycemic Agents; Hypothyroidism; Metformin; Overweight; Polycystic Ovary Syndrom | 2011 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Liver; Metabolic Syndrome; Metformin; O | 2011 |
Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.
Topics: Adolescent; Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Homeostasis; Homocysteine; H | 2012 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome.
Topics: Adolescent; Estrogens; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Metformin; | 2013 |
What's preventing us from preventing type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Approval; Glucose Intolerance; Humans; Hypoglycemic Agents; Insuranc | 2012 |
Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography.
Topics: Adult; Case-Control Studies; Endometrium; Female; Humans; Hypoglycemic Agents; Imaging, Three-Dimens | 2013 |
Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes.
Topics: Adipocytes; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Transporter Type 4; Humans; Insulin; | 2013 |
[The rehabilitation of metformin].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyp | 2005 |
[Metformin in the treatment of type 2 diabetes in overweighted or obese patients].
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; | 2005 |
[Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?].
Topics: Adult; Aged; Autoantibodies; Autoimmune Diseases; Body Mass Index; Confidence Intervals; Diabetes Me | 2007 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy | 2007 |
Exenatide: new drug. Type 2 diabetes for some overweight patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptid | 2007 |
[Insulin-using woman with type 2 diabetes and weight problems].
Topics: C-Peptide; Caloric Restriction; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Exercise T | 2008 |
Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver.
Topics: Animals; Diet, Atherogenic; Drug Evaluation, Preclinical; Hypertriglyceridemia; Hypoglycemic Agents; | 2008 |
Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Topics: Adipose Tissue; Adult; Androgens; Biopsy; Blood Glucose; Cytokines; Estradiol; Female; GPI-Linked Pr | 2008 |
Doctors seek to prevent breast cancer recurrence by lowering insulin levels.
Topics: Adenylate Kinase; Antineoplastic Agents; Breast Neoplasms; Canada; Clinical Trials as Topic; Exercis | 2008 |
Antipsychotic-induced weight gain in patients with schizophrenia.
Topics: Antipsychotic Agents; Exercise; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth | 2008 |